{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.17944"}, {"@name": "filename", "#text": "24777_DISSERTA%c3%87%c3%83O%20ANA%20PATRICIA%20DE%20OLIVEIRA%20SOUZA.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE FEDERAL DE PERNAMBUCO  \n\nCENTRO DE CI\u00caNCIAS DA SA\u00daDE \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM ODONTOLOGIA  \n\nMESTRADO EM ODONTOLOGIA \n\n\u00c1REA DE CONCENTRA\u00c7\u00c3O EM CL\u00cdNICA INTEGRADA \n\n \n\nANA PATR\u00cdCIA DE OLIVEIRA SOUZA \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAVALIA\u00c7\u00c3O DA ASSOCIA\u00c7\u00c3O DE UMA BIOCER\u00c2MICA DE FOSFATO DE \n\nC\u00c1LCIO COM C\u00c9LULAS-TRONCO MESENQUIMAIS DE CORD\u00c3O \n\nUMBILICAL HUMANO NA BIOENGENHARIA DO TECIDO \u00d3SSEO \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nRecife \u2013 PE \n\n2013 \n\n\n\n \n\n \n\nUNIVERSIDADE FEDERAL DE PERNAMBUCO  \n\nCENTRO DE CI\u00caNCIAS DA SA\u00daDE \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM ODONTOLOGIA  \n\nMESTRADO EM ODONTOLOGIA  \n\nAREA DE CONCENTRA\u00c7\u00c3O EM CL\u00cdNICA INTEGRADA \n\n \n\nANA PATR\u00cdCIA DE OLIVEIRA SOUZA \n\n \n\n \n\nAVALIA\u00c7\u00c3O DA ASSOCIA\u00c7\u00c3O DE UMA BIOCER\u00c2MICA DE FOSFATO DE \n\nC\u00c1LCIO COM C\u00c9LULAS-TRONCO MESENQUIMAIS DE CORD\u00c3O \n\nUMBILICAL HUMANO NA BIOENGENHARIA DO TECIDO \u00d3SSEO \n\n \n\n \n\nDisserta\u00e7\u00e3o apresentada ao Colegiado da P\u00f3s-\n\nGradua\u00e7\u00e3o em Odontologia do Centro de Ci\u00eancias da \n\nSa\u00fade da Universidade Federal de Pernambuco, como \n\nrequisito parcial para obten\u00e7\u00e3o do grau de mestre em \n\nOdontologia com \u00e1rea de concentra\u00e7\u00e3o em Cl\u00ednica \n\nIntegrada. \n\nOrientadora: Profa. Dra. Alessandra de \nAlbuquerque Tavares de Carvalho  \nCo-Orientadora: Profa. Dr. M\u00e1rcia Bezerra da \nSilva  \n\n \n\n \n\n \n\n \n\nRecife \u2013PE \n\n2013 \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\nT\u00cdTULO DO TRABALHO: AVALIA\u00c7\u00c3O DA ASSOCIA\u00c7\u00c3O DE UMA \n\nBIOCER\u00c2MICA DE FOSFATO DE C\u00c1LCIO COM C\u00c9LULAS-TRONCO \n\nMESENQUIMAIS DE CORD\u00c3O UMBILICAL HUMANO NA BIOENGENHARIA \n\nDO TECIDO \u00d3SSEO \n\n \n\n \n\nNOME DO ALUNO: Ana Patr\u00edcia de Oliveira Souza \n\n \n\n \n\n \n\n \n\nDISSERTA\u00c7\u00c3O APRESENTADA EM: 29/08/2013 \n\n \n\n \n\n \n\nMEMBROS DA BANCA EXAMINADORA: \n\nProf\na\n. Dr\n\na\n. Liriane Baratella Ev\u00eancio__________________________________ \n\nProf\na\n. Dr\n\na\n. Paloma Lys de Medeiros___________________________________ \n\nProf\na\n. Dr\n\na\n. Fl\u00e1via Maria de Moraes Ramos Perez_________________________ \n\n \n\n \n\n \n\n \n\n \n\nRecife \u2013PE \n\n2013 \n\n \n\n\n\n \n\n \n\nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nREITOR \n\nProf. Dr. An\u00edsio Brasileiro de Freitas Dourado \n\nVICE-REITOR \n\nProf. Dr. Silvio Romero de Barros Marques \n\nPR\u00d3-REITOR DA P\u00d3S-GRADUA\u00c7\u00c3O \n\nProf. Dr. Francisco de Souza Ramos \n\nCENTRO DE CI\u00caNCIAS DA SA\u00daDE \n\nDIRETOR \n\n Prof. Dr. Nicodemos Teles de Pontes Filho  \n\nCOORDENADOR DA P\u00d3S-GRADUA\u00c7\u00c3O EM ODONTOLOGIA \n\nProfa.Dra. Jurema Freire Lisboa de Castro \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM ODONTOLOGIA \n\nMESTRADO EM CL\u00cdNICA INTEGRADA \n\nCOLEGIADO \n\nMEMBROS PERMANENTES \n\nProfa. Dra. Alessandra Albuquerque T. Carvalho \n\nProf. Dr. Anderson Stevens Le\u00f4nidas Gomes \n\nProf.Dr. Arnaldo de Fran\u00e7a Caldas Junior \n\nProf. Dr. Carlos Menezes Aguiar \n\nProf.Dr. Danyel Elias da Cruz Perez \n\nProf. Dr. Edvaldo Rodrigues de Almeida \n\nProfa.Dra. Flavia Maria de Moraes Ramos Perez \n\nProf. Dr. Jair Carneiro Le\u00e3o \n\nProfa. Dra. Jurema Freire Lisboa de Castro \n\nProfa. Dra. Liriane Baratella Ev\u00eancio \n\nProf.Dr. Luiz Alcino Monteiro Gueiros \n\nProf.Dra. Maria Luiza dos Anjos Pontual \n\nProf.Dr. Paulo S\u00e1vio Angeiras Goes \n\nProfa. Dra. Renata Cim\u00f5es Jovino Silveira \n\nProfa.Dra. Silvia Regina Jamelli \n\nProf.Dra. Simone Guimaraes Farias Gomes \n\nProf.Dr. Tib\u00e9rio C\u00e9sar Uchoa Matheus \n\nMEMBRO COLABORADOR \n\nProf. Dr. Cl\u00e1udio Heliomar Vicente da Silva \n\nProfa. Dra. L\u00facia Carneiro de Souza Beatrice \n\nSECRETARIA \n\nOziclere  Sena de Ara\u00fajo \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                                       Dedico essa Disserta\u00e7\u00e3o a todos aqueles                 \n\nque s\u00e3o a raz\u00e3o da minha vida:  \n\n                                                     Meus filhos Thiago e Gabriel, meu marido \n\nGiovani e Socorro minha m\u00e3e. \n\n                                                 Dedico tamb\u00e9m a todos aqueles que foram \n\namigos e deram-me apoio nessa grande conquista  \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\nAGRADECIMENTOS \n\n Agrade\u00e7o a Deus por permitir mais essa conquista e ser sempre meu \n\nref\u00fagio e fortaleza. \n\n \u00c0 minha orientadora, Prof\na\n. Dra. Alessandra Albuquerque T. Carvalho, \n\npela amizade, apoio, confian\u00e7a e dedica\u00e7\u00e3o, durante todo o Mestrado. \n\n \u00c0 minha co-orientadora Prof\na\n Dr\n\na\n M\u00e1rcia Bezerra da Silva e a Prof\n\na\n Dr\n\na\n \n\nPaloma Lys de Medeiros, pela compet\u00eancia, dedica\u00e7\u00e3o, apoio, amizade, \n\nempenho e empolga\u00e7\u00e3o na realiza\u00e7\u00e3o da pesquisa.  \n\n A todos que colaboraram carinhosamente para a realiza\u00e7\u00e3o do nosso \n\ntrabalho: Dr\na\n. Val\u00e9ria Rego Alves Pereira do Centro de Pesquisa Ageu \n\nMagalh\u00e3es (CPqAM/FIOCRUZ/PE),  Jeann Fabiann Branco J\u00fanior (aluno de \n\ninicia\u00e7\u00e3o cient\u00edfica do Centro de Pesquisa Ageu Magalh\u00e3es \n\n(CPqAM/FIOCRUZ/PE), Prof. Cl\u00e1udio Rodrigues do Departamento de Biof\u00edsica \n\ne Radiobiologia CCB//UFPE e Prof. Reginaldo Pereira do Departamento de \n\nFisiologia e Farmacologia CCB/UFPE.  \n\n A todos os professores que fazem parte do Programa de P\u00f3s-Gradua\u00e7\u00e3o \n\nem Odontologia e empenham-se em tornar-nos Mestres, dando-nos a melhor \n\ndas li\u00e7\u00f5es com seu exemplo. \n\n A todos os colegas do mestrado pelos momentos compartilhados e em \n\nespecial \u00e0queles que se fizeram presentes nas horas certas. \n\n Aos funcion\u00e1rios do Curso de Odontologia, em especial a Dona Rita de \n\nEstomatologia e da P\u00f3s-Gradua\u00e7\u00e3o destacando, Dona T\u00e2nia e Oziclere Sena.  \n\n \u00c0 minha fam\u00edlia e pacientes por todo apoio carinho e compreens\u00e3o, \n\napoiando-me em todos os momentos, auxiliando-me na realiza\u00e7\u00e3o desse ideal. \n\nAos meus pacientes. \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                       \"Quando uma criatura humana desperta para um                                                                                                            \n\ngrande sonho e sobre ele lan\u00e7a                                                                       \n\ntoda a for\u00e7a de sua alma,                                                                                \n\ntodo o universo conspira a seu favor.\" \n\nJohann Goethe  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\nRESUMO \n\n  \n\n       T\u00e9cnicas e biomateriais v\u00eam sendo testados e utilizados, todos com suas \n\nvantagens e desvantagens, assim como limita\u00e7\u00f5es principalmente com rela\u00e7\u00e3o \n\nao tamanho da reconstru\u00e7\u00e3o e \u00e0 necessidade de um leito receptor adequado, \n\nque proporcione a vasculariza\u00e7\u00e3o, nutri\u00e7\u00e3o e fornecimento de c\u00e9lulas em boa \n\nquantidade para o processo de neoforma\u00e7\u00e3o \u00f3ssea. Foi realizado um estudo in \n\nvitro associando c\u00e9lulas-tronco mesenquimais (CTMs) de cord\u00e3o umbilical \n\nhumano com uma biocer\u00e2mica fosfac\u00e1lcica bif\u00e1sica nano-micro-macro porosa \n\nde hidroxiapatita - beta tric\u00e1lcio fosfato (HA-?TCP) densa. A propor\u00e7\u00e3o de \n\nhidroxiapatita (HA) foi de 60% e ?TCP 40% com micro poros de 10 micra de \n\ndi\u00e2metro e di\u00e2metro dos poros intercomunicantes de at\u00e9 500 micra. O \n\nexperimento foi mantido em estufa a 37\u00ba por 21 dias e as trocas do meio de \n\ncultura realizadas a cada 03 dias. As amostras foram analisadas \n\nsemanalmente at\u00e9 21 dias por microsc\u00f3pio invertido de contraste de fase e \n\nap\u00f3s os 21 dias foi realizada a an\u00e1lise citoqu\u00edmica das amostras com o m\u00e9todo \n\ndo vermelho de alizarina. Os resultados demonstraram que a morfologia das \n\nCTMs em estudo condiz com o achado de que a estimula\u00e7\u00e3o das mesmas pela \n\npresen\u00e7a do biomaterial foi capaz de produzir c\u00e9lulas possivelmente secretoras \n\ndemostrando que a associa\u00e7\u00e3o da biocer\u00e2mica Osteosynt\u00ae com c\u00e9lulas-tronco \n\nmesenquimais de cord\u00e3o umbilical humano \u00e9 um campo bastante promissor na \n\nbioengenharia de tecido \u00f3sseo.  \n\nPalavras-chave: Bioengenharia. Biocer\u00e2mica. C\u00e9lulas-tronco mesenquimais. \n\nOsteoblastos. Indutores. \n\n \n\n\n\n \n\n \n\nABSTRACT \n\n         \n\nBiomaterials and techniques have been tested and used, all with their \n\nadvantages and disadvantages, and limitations, especially with respect to the \n\nsize of the reconstruction and the need for a good receiver site, providing \n\nvascularization, nutrition and supply of cells in good quantity for process of bone \n\nformation. Was conducted an in vitro study involving mesenchymal stem cells \n\n(MSCs) from human umbilical cord with a biphasic calcium phosphate \n\nbioceramic nano-micro-macro porous hydroxyapatite beta - tricalcium \n\nphosphate (HA-?TCP) dense. The ratio is 60% HA and 40% ?TCP microspores \n\nwith a diameter of 10 microns and interconnecting pores of diameter up to 500 \n\nmicrons. The experiment was held at 37 for 21 days and exchange of culture \n\nvehicle taken every 03 days. The samples were analyzed weekly up to 21 days \n\nby inverted microscope and phase contrast after 21 days carried out \n\ncytochemical analysis of samples with the method of Alizarin Red. The results \n\nshow that the morphology of MSCs under study is consistent with the finding \n\nthat stimulation of the same by the presence of the biomaterial was able to \n\nproduce cells secreting possibly demonstrating the association of bioceramic \n\nOsteosynt \u00ae with mesenchymal stem cells from human umbilical cord is a \n\npromising in the ground of bone tissue bioengineering. \n\nKeywords: Bioengineering. Bioceramic. Stem cells mesenchymal. Osteoblasts. \n\nInductors. \n\n \n\n \n\n \n\n\n\n \n\n \n\nLISTA DE ILUSTRA\u00c7\u00d5ES \n\nFigura 1 Reabsor\u00e7\u00e3o e neoforma\u00e7\u00e3o \u00f3ssea  20 \n\nFigura 2 Pe\u00e7as prototipadas de ossos de diversas partes do corpo \n\npara reconstru\u00e7\u00e3o \n\n23 \n\nFigura 3. Foto de cord\u00e3o umbilical humano na etapa inicial do \n\nprocesso de isolamento das c\u00e9lulas-tronco mesenquimais   \n\n26 \n\nFigura 4. Capela de fluxo laminar onde o botton da biocer\u00e2mica foi            \n\nseccionado com o motor Surgic XT NSK e pe\u00e7a de m\u00e3o Kavo \n\nacoplado       com disco de a\u00e7o. \n\n27 \n\nFigura 5. Placa de 96 po\u00e7os contendo amostras da biocer\u00e2mica, meio \n\ne c\u00e9lulas-tronco mesenquimais de cord\u00e3o umbilical humano \n\n28 \n\nFigura 6. Avalia\u00e7\u00e3o semanal da cultura com o microsc\u00f3pio Leica 28 \n\nFigura 7: As c\u00e9lulas sendo examinadas ao microsc\u00f3pio invertido \n\n(LEICA DMIL; Leica Microsystems GmbH, Bensheim, Alemanha) \n\ne sendo feita a capta\u00e7\u00e3o das imagens com uma c\u00e2mera de v\u00eddeo \n\nCCD  \n\n(Motic 2000; Quimis Diadema, SP, Brasil) acoplada ao microsc\u00f3pio \n\n29 \n\nFigura 8. Fotomicrografia de c\u00e9lulas-tronco mesenquimais de                     \n\ncord\u00e3o        umbilical humano cultivadas in vitro, realizada com aux\u00edlio \n\nde microsc\u00f3pio invertido de contraste de fase. Observa-se forma\u00e7\u00e3o \n\nde monocamada com t\u00edpicas c\u00e9lulas fibroblast\u00f3ide.                                         \n\nEscala de barra = 50 \u00b5m. \n\n30 \n\nFIGURA 9: An\u00e1lise por citometria de fluxo da express\u00e3o de \n\nmarcadores de superf\u00edcie de c\u00e9lulas-tronco mesenquimais do cord\u00e3o \n\numbilical humano. Os dados mostrados s\u00e3o do fen\u00f3tipo de c\u00e9lulas \n\nanalisadas no final da terceira passagem. O controle \u00e9 mostrado em \n\nvermelho \n\n30 \n\n\n\n \n\n \n\nFigura 10. Fotomicrografia da biocer\u00e2mica fosfoc\u00e1lcica bif\u00e1sica porosa \n\nde HA-?TCP em associa\u00e7\u00e3o com c\u00e9lulas-tronco mesenquimais de \n\ncord\u00e3o umbilical, realizadas com aux\u00edlio de microsc\u00f3pio invertido de \n\ncontraste de fase. C\u00e9lulas fibroblast\u00f3ide s\u00e3o observadas pr\u00f3ximas ao \n\n\u00fanico bloco de cer\u00e2mica (estrela).Escala de barra = 100 \u00b5m. \n\n32 \n\nFigura 11: Fotomicrografia de c\u00e9lulas-tronco mesenquimais de cord\u00e3o  \n\numbilical humano cultivadas em associa\u00e7\u00e3o com a biocer\u00e2mica \n\nfosfoc\u00e1lcica bif\u00e1sica porosa de HA-?TCP, em diferencia\u00e7\u00e3o \n\nosteog\u00eanica coradas com solu\u00e7\u00e3o vermelho de Alizarina e \n\nvisualizadas com aux\u00edlio de microsc\u00f3pio invertido de contraste de fase \n\nEscala de barra = 50 \u00b5m. \n\n33 \n\nFigura 12. Fotomicrografia da morfologia de c\u00e9lulas-tronco \n\nmesenquimais de cord\u00e3o umbilical humano induzidas \u00e0 diferencia\u00e7\u00e3o \n\nosteog\u00eanica pela biocer\u00e2mica fosfoc\u00e1lcica bif\u00e1sica porosa de HA-\n\n?TCP (fragmentos castanhos). Culturas avaliadas com aux\u00edlio de \n\nmicrosc\u00f3pio invertido: sem contraste de fase (A) e com contraste de \n\nfase (B). Escala de barra = 100. \n\n33 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\nLISTA DE SIGLAS E ABREVIATURAS \n\n \n\nBMPs: prote\u00ednas \u00f3sseas morfogen\u00e9ticas \n\n?TPC: beta tric\u00e1lcio fosfato \n\nCPqAM: Centro de Pesquisas Ageu Magalh\u00e3es \n\nCT: c\u00e9lulas-tronco \n\nCTMs: c\u00e9lulas-tronco mesenquimais \n\nDMEM: Dulbecco's Modified Eagle Medium \n\nEDTA: \u00e1cido etilenodiamino tetra-ac\u00e9tico \n\nFIOCRUZ: Funda\u00e7\u00e3o Oswaldo Cruz \n\nFITC: fluorescein isothiocyanate \n\nHA: hidroxiapatita \n\nHA-?TCP: hidroxiapatita-beta-tric\u00e1lcio fosfato \n\nPBS: fosfato de s\u00f3dio e cloreto \n\nSFB: soro fetal bovino \n\nTGF: fator de transforma\u00e7\u00e3o do crescimento \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\nSUM\u00c1RIO \n\n \n\n \n\n1 INTRODU\u00c7\u00c3O                                                                                                14 \n\n2 REVIS\u00c3O DA LITERATURA                                                                           17 \n\n3 MATERIAIS E M\u00c9TODOS                                                                              23 \n\n3.1.Considera\u00e7\u00f5es bio\u00e9ticas 23 \n\n3.2.Localiza\u00e7\u00e3o do estudo                                                                                23 \n\n3.3 Tipo de estudo                                                                                             23 \n\n3.4. Tamanho da amostra                                                                                  23 \n\n3.5. Obten\u00e7\u00e3o da cultura de c\u00e9lulas-tronco 23 \n\n3.5.1. Coleta de cord\u00e3o umbilical humano                                                         23 \n\n3.5.2. Isolamento e cultivo das c\u00e9lulas-tronco mesenquimais \n\n(MSCs)     \n\n24 \n\n3.5.3. Imunofenotipagem das CTMs                                                                 25 \n\n3.5.4. Cultivo das c\u00e9lulas-tronco com a biocer\u00e2mica 26 \n\n3.5.5. Avalia\u00e7\u00e3o das caracter\u00edsticas morfol\u00f3gicas das CTMs  27 \n\n3.5.6. An\u00e1lise das c\u00e9lulas diferenciadas 28 \n\n4 RESULTADOS E DISCUSS\u00c3O 28 \n\n4.1. Isolamento e cultivo das CTMs de cord\u00e3o umbilical humano 28 \n\n4.2. An\u00e1lise da imunofenotipagem das CTMs                                                   29 \n\n4.3. Morfologia das CTMs durante o processo de diferencia\u00e7\u00e3o  \n\nosteog\u00eanica sobre a biocer\u00e2mica                                                                      \n\n30 \n\n5 CONCLUS\u00d5ES 33 \n\nREFER\u00caNCIAS  34 \n\n\n\n \n\n \n\nAP\u00caNDICE: Termo de consentimento livre e esclarecido                                 37 \n\nANEXO: Normas da revista Acta Biomaterialia                                                 39 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n15 \n\n \n\n \n\n1. INTRODU\u00c7\u00c3O \n\n Perdas \u00f3sseas na face podem impossibilitar reabilita\u00e7\u00f5es prot\u00e9ticas e \n\ncausar deforma\u00e7\u00f5es comprometendo a est\u00e9tica do paciente.  \n\nPara o processo de reconstru\u00e7\u00e3o \u00f3ssea necessitamos de uma matriz, \n\nosteocondu\u00e7\u00e3o, osteoindu\u00e7\u00e3o e osteog\u00eanese. Para haver osteog\u00eanese \n\nnecessita-se de c\u00e9lulas \u00f3sseas, que atualmente s\u00e3o encontradas em enxertos \n\naut\u00f3genos ou em tecido \u00f3sseo sadio adjacente ao local da reconstru\u00e7\u00e3o. A \n\nmaior concentra\u00e7\u00e3o de c\u00e9lulas encontra-se no osso esponjoso. \n\nA regenera\u00e7\u00e3o de grandes defeitos \u00f3sseos \u00e9 um problema cl\u00ednico \n\nsignificativo e comum que apresenta limita\u00e7\u00f5es nos tratamentos j\u00e1 existentes, \n\ncomo enxertos \u00f3sseos aut\u00f3logos e aloenxertos, aumentando a necessidade de \n\npesquisas com substitutos \u00f3sseos sint\u00e9ticos (WEI X, et al. 2013). Xenoenxertos \n\ncomo Bio-Oss\u00ae e Osteograf funcionam como substitutos \u00f3sseos naturais, s\u00e3o \n\nderivados do componente mineral de ossos bovinos e s\u00e3o muito semelhantes \n\naos ossos humanos, por\u00e9m apresentam alto grau de reabsor\u00e7\u00e3o (COELHO, \n\n2013). \n\n \nDentre os biomateriais pesquisados, as biocer\u00e2micas a base de fosfato \n\nde c\u00e1lcio s\u00e3o as que apresentam potencial aplicabilidade na substitui\u00e7\u00e3o e \n\nregenera\u00e7\u00e3o do tecido \u00f3sseo, pois apresentam caracter\u00edsticas espec\u00edficas tais \n\ncomo, composi\u00e7\u00e3o qu\u00edmica semelhante \u00e0 fase mineral de ossos, boa \n\nbiocompatibilidade, bioatividade, aus\u00eancia de toxicidade local ou sist\u00eamica e \n\ncapacidade de ligar-se ao tecido hospedeiro ou ser absorvida pelo tecido vivo \n\n(RODRIGUES, et al., 2012). \n\nAloenxertos, xenoenxertos e biomateriais a base hidroxiapatita e beta \n\ntric\u00e1lcio fosfato s\u00e3o uma \u00f3tima matriz para neoforma\u00e7\u00e3o \u00f3ssea, por\u00e9m seu \n\nhttp://www.sciencedirect.com/science/article/pii/S174270611300278X\n\n\n16 \n\n \n\n \n\npadr\u00e3o de reabsor\u00e7\u00e3o n\u00e3o pode ser controlado e n\u00e3o apresentam c\u00e9lulas \n\n\u00f3sseas, portanto n\u00e3o s\u00e3o osteog\u00eanicos. Aloenxertos e xenoenxertos t\u00eam ainda \n\na desvantagem de pequeno potencial de antigenicidade e risco de transmiss\u00e3o \n\nde doen\u00e7as (MORI, et al., 2010).  \n\nA remodela\u00e7\u00e3o \u00f3ssea \u00e9 um sistema complexo que ocorre em uma matriz \n\nem fun\u00e7\u00e3o do equil\u00edbrio entre reabsor\u00e7\u00e3o pelos osteocl\u00e1stos e neoforma\u00e7\u00e3o \n\n\u00f3ssea pelos osteoblastos envolvendo a indu\u00e7\u00e3o de c\u00e9lulas osteoprogenitoras \n\npor fatores de crescimento, dentre eles fator de transforma\u00e7\u00e3o do crescimento \n\n(TGF) e prote\u00ednas \u00f3sseas morfogen\u00e9ticas (BMPs) (GUERRERO, et al., 2013). \n\nV\u00e1rios estudos t\u00eam relatado a import\u00e2ncia de pesquisas com c\u00e9lulas-\n\ntronco mesenquimais para a engenharia de tecido \u00f3sseo (OLIVEIRA, 2008). \n\nEm casos de reconstru\u00e7\u00f5es de mandibulectomias, o leito receptor n\u00e3o \u00e9 \n\nadequado, n\u00e3o tem suporte e n\u00e3o apresenta c\u00e9lulas progenitoras suficientes \n\npara induzir a neoforma\u00e7\u00e3o \u00f3ssea com o biomaterial.   A possibilidade de \n\nreconstru\u00e7\u00e3o \u00f3ssea na regi\u00e3o cr\u00e2nio-facial, com pe\u00e7as de biocer\u00e2mica \n\nconfeccionadas atrav\u00e9s de prototipagem, traria um benef\u00edcio enorme para \n\npacientes que tiveram perdas \u00f3sseas nessas regi\u00f5es, restaurando a anatomia \n\ndo defeito \u00f3sseo causado por perdas dent\u00e1rias, traumatismos ou patologias.  \n\nO biomaterial do presente estudo foi uma biocer\u00e2mica fosfac\u00e1lcica \n\nbif\u00e1sica nano-micro-macro porosa de HA-?TCP ( hidroxiapatita beta-tric\u00e1lcio \n\nfosfato) com caracter\u00edsticas e propriedades f\u00edsico-qu\u00edmicas semelhantes \u00e0 \n\nmatriz mineral do tecido \u00f3sseo. A propor\u00e7\u00e3o de hidroxiapatita (HA) foi de 60% e \n\nbeta-tric\u00e1lcio-fosfato (?TCP) foi de 40% com micro poros de 10 micra de \n\ndi\u00e2metro e di\u00e2metro dos poros intercomunicantes de at\u00e9 500 micra. Com essa \n\nbiocer\u00e2mica de fosfato de c\u00e1lcio pode-se confeccionar pe\u00e7as individualizadas \n\n\n\n17 \n\n \n\n \n\ncom o formato do osso da face que estiver comprometido e do tamanho \n\nnecess\u00e1rio atrav\u00e9s da prototipagem 3D. Foi realizado um estudo in vitro da \n\nassocia\u00e7\u00e3o de c\u00e9lulas-tronco com a biocer\u00e2mica para avaliar atrav\u00e9s da \n\nmicroscopia invertida de fase a osteoindu\u00e7\u00e3o do biomaterial nas c\u00e9lulas-tronco \n\nde cord\u00e3o umbilical e o potencial osteog\u00eanico do biomaterial atrav\u00e9s do m\u00e9todo \n\ndo vermelho de alizarina. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n18 \n\n \n\n \n\n2. REVIS\u00c3O DA LITERATURA \n\n \n\nA reabsor\u00e7\u00e3o \u00f3ssea alveolar que ocorre ap\u00f3s perda do elemento \n\ndent\u00e1rio, traumatismos dentais, traumatismos faciais e patologias \u00f3sseas, leva \n\na perda de suporte \u00f3sseo para reabilita\u00e7\u00f5es prot\u00e9ticas e deformidades faciais. \n\nOs efeitos s\u00e3o maiores em deformidades localizadas na regi\u00e3o anterior dos \n\nmaxilares ou envolvendo grandes perdas \u00f3sseas (OLIVEIRA, 2008). \n\nA reconstru\u00e7\u00e3o de processos alveolares com enxertos \u00f3sseos foi um dos \n\naspectos proeminentes para o avan\u00e7o da implantodontia. Entre as t\u00e9cnicas \n\ncir\u00fargicas para reabilitar maxilares atr\u00f3ficos est\u00e3o \u00e0s menos invasivas como \n\npequenos enxertos \u00f3sseos e implantes curtos e procedimentos mais \n\ncomplexos como enxertos \u00f3sseos associados \u00e0 cirurgia ortogn\u00e1tica (LUBIANA \n\net al, 2007). \n\nOutra alternativa no processo de enxertias \u00e9 o aloenxerto que serve \n\ncomo uma matriz osteocondutora para neoforma\u00e7\u00e3o \u00f3ssea e est\u00e1 dispon\u00edvel \n\nem grandes quantidades sem necessidade de um segundo local cir\u00fargico para \n\nsua remo\u00e7\u00e3o, diminuindo sua morbidade (PELEGRINE; MACEDO; COSMO, \n\n2008). \n\nO \u00fanico material osteog\u00eanico \u00e9 o osso aut\u00f3geno e sua forma mais eficaz \n\n\u00e9 o osso esponjoso, pois fornece a maior concentra\u00e7\u00e3o de c\u00e9lulas \u00f3sseas. Na \n\nFase I, com a osteog\u00eanese ocorre forma\u00e7\u00e3o de um produto oste\u00f3ide \n\nproporcionalmente ao n\u00famero de c\u00e9lulas transplantadas principalmente da \n\npor\u00e7\u00e3o esponjosa do enxerto aut\u00f3geno. As c\u00e9lulas sobrevivem nos primeiros 3 \n\nou 4 dias pela nutri\u00e7\u00e3o do tecido celular subjacente. Na Fase II, osteoindu\u00e7\u00e3o, \n\nas c\u00e9lulas do tecido receptor promovem a reabsor\u00e7\u00e3o das c\u00e9lulas \n\n\n\n19 \n\n \n\n \n\ntransplantadas que morrem e liberam as prote\u00ednas indutoras e os fatores de \n\ncrescimento. Come\u00e7a ap\u00f3s aproximadamente seis semanas e dura no m\u00ednimo \n\nseis meses. O osso cortical \u00e9 a fonte prim\u00e1ria das prote\u00ednas morfogen\u00e9ticas. \n\nNa Fase III, osteocondu\u00e7\u00e3o, a matriz inorg\u00e2nica de hidroxiapatita forma uma \n\nplataforma no enxerto \u00f3sseo contribuindo para o efeito osteocondutor \u00e0 medida \n\nque ocorre a substitui\u00e7\u00e3o \u00f3ssea como na Figura 1 (ZERBO, 2001). \n\nO osso aut\u00f3geno \u00e9 considerado o \u201cpadr\u00e3o ouro\u201d para reconstru\u00e7\u00e3o de \n\nrebordos alveolares, pois apesar de perder boa parte de sua vitalidade celular \n\nrevasculariza-se e incorpora-se ao leito receptor, possibilitando a \n\nosseointegra\u00e7\u00e3o de implantes (VASCONCELOS; PETRILLI; PALECKIS, 2006). \n\nOs alopl\u00e1sticos s\u00e3o materiais sint\u00e9ticos bio-inertes e outros bio-ativos. A \n\nhidroxiapatita, o fosfato tric\u00e1lcio, a fenoapatita e o biovidro s\u00e3o bio-ativos, pois \n\nreagem com o meio em torno deles. Apresentam-se como blocos s\u00f3lidos, \n\nporosos ou os dois. Os s\u00f3lidos s\u00e3o reabsorvidos mais lentamente que os \n\nporosos da mesma composi\u00e7\u00e3o. Quando ambos s\u00e3o porosos, o fosfato \n\ntric\u00e1lcico reabsorve mais r\u00e1pido que a hidroxiapatita por ser cristalina e menos \n\nsol\u00favel (NEVES, 2001). \n\nOs enxertos alopl\u00e1sticos s\u00e3o osteocondutores, exclusivamente sint\u00e9ticos \n\ne biocompat\u00edveis. S\u00e3o vendidos em uma grande variedade de texturas, \n\ntamanhos de part\u00edculas e formatos. Podem ser separados em cer\u00e2micos, \n\npol\u00edmeros e combina\u00e7\u00f5es. As cer\u00e2micas podem ser: Bio-inertes, que n\u00e3o tem \n\nuni\u00e3o direta com o osso receptor e s\u00e3o presas mecanicamente em contato com \n\no osso. O tipo de cicatriza\u00e7\u00e3o em um implante osseointegrado bio-inerte \u00e9 um \n\nprocesso osteocondutor; por exemplo, \u00f3xido de alum\u00ednio e \u00f3xido de tit\u00e2nio. Bio-\n\nativas, as quais se unem ao osso e agem como um substrato para o \n\n\n\n20 \n\n \n\n \n\ncrescimento \u00f3sseo e por isto constituem a maior fam\u00edlia de aloplastos usados \n\npara enxerto em implantodontia. S\u00e3o osteocondutoras e osteoindutoras mas \n\nn\u00e3o osteog\u00eanicas; por exemplo, fosfato de c\u00e1lcio e hidroxiapatita sint\u00e9tica \n\n(MISCH, 2006). \n\n \nFigura 1 Reabsor\u00e7\u00e3o e neoforma\u00e7\u00e3o \u00f3ssea (PELEGRINE; MACEDO; COSMO, \n\n2008). \n\n          O processo de reconstru\u00e7\u00e3o \u00f3ssea necessita apresentar princ\u00edpios \n\norg\u00e2nicos que influenciam diretamente a osteog\u00eanese que s\u00e3o: A matriz \n\n(arcabou\u00e7o local) ou material usado para reconstru\u00e7\u00e3o; c\u00e9lulas-tronco \n\nprogenitoras para diferencia\u00e7\u00e3o e multiplica\u00e7\u00e3o; prote\u00ednas sinalizadoras de \n\nindu\u00e7\u00e3o da transforma\u00e7\u00e3o das c\u00e9lulas mesenquimais indiferenciadas ou \n\nc\u00e9lulas-tronco em osteoblastos e em outras c\u00e9lulas especializadas e condi\u00e7\u00f5es \n\nlocais e org\u00e2nicas para permitir neoforma\u00e7\u00e3o vascular (angiog\u00eanese) para \n\nnutri\u00e7\u00e3o e viabiliza\u00e7\u00e3o do processo (PELLEGRINE, MACEDO E COSMO, \n\n2008). \n\n           A regenera\u00e7\u00e3o tecidual guiada usando hidroxiapatita bif\u00e1sica+ beta-\n\ntric\u00e1lcio-fosfato (Bone Ceramic) ou osso mineral natural coberto com col\u00e1geno \n\n\n\n21 \n\n \n\n \n\n(BioOss Collagen) foi comprovadamente eficaz, e ambos apresentam \n\npropriedade de osteocondu\u00e7\u00e3o (SCHWARZ et al., 2007). \n\nA composi\u00e7\u00e3o qu\u00edmica e estrutura f\u00edsica de um biomaterial exercem \n\ninflu\u00eancias diretas no comportamento celular, levando a diferentes respostas \n\nteciduais. A exist\u00eancia de uma matriz que, al\u00e9m de ser biocompat\u00edvel e de \n\napresentar micro e macroporos intercomunicantes, permita a ades\u00e3o e a \n\ndiferencia\u00e7\u00e3o osteog\u00eanica de c\u00e9lulas-tronco, \u00e9 essencial para a bioengenharia \n\nde tecido \u00f3sseo (SILVEIRA et al., 2006).  \n\nV\u00e1rios tipos celulares est\u00e3o em investiga\u00e7\u00e3o em experimentos animais, \n\npor\u00e9m o maior potencial terap\u00eautico est\u00e1 nas c\u00e9lulas-tronco. Estas c\u00e9lulas \n\npossuem capacidade de prolifera\u00e7\u00e3o indefinida, auto renova\u00e7\u00e3o, produ\u00e7\u00e3o de \n\ndiferentes linhagens celulares e regenera\u00e7\u00e3o de tecidos. Est\u00e3o presentes \n\nprincipalmente em embri\u00f5es, c\u00e9lulas-tronco (CT) embrion\u00e1rias, no cord\u00e3o \n\numbilical e na medula \u00f3ssea que s\u00e3o chamadas de c\u00e9lulas-tronco adultas \n\n(SILVEIRA et al., 2006).  \n\nAs c\u00e9lulas-tronco s\u00e3o classificadas de acordo com sua plasticidade, isto \n\n\u00e9, seu potencial de diferencia\u00e7\u00e3o nos diversos tecidos. As c\u00e9lulas-tronco \n\nembrion\u00e1rias s\u00e3o c\u00e9lulas totipotentes, ou seja, t\u00eam uma grande capacidade de \n\ndiferencia\u00e7\u00e3o e de divis\u00e3o, podendo diferenciar-se em todos os tipos de tecido \n\ndo corpo. As c\u00e9lulas-tronco adultas s\u00e3o c\u00e9lulas pluripotentes que t\u00eam a \n\ncapacidade de diferenciar-se em muitos tecidos, por\u00e9m n\u00e3o em todos. Seu \n\npotencial de replica\u00e7\u00e3o, diferentemente das embrion\u00e1rias \u00e9 limitado (PERES; \n\nCURI, 2005). Elas podem ser encontradas em diversos tecidos do corpo como \n\nreservas end\u00f3genas teciduais, sangue perif\u00e9rico, placenta, sangue do cord\u00e3o \n\numbilical, c\u00e9lulas perivasculares e medula \u00f3ssea, sendo esta a que mais se \n\n\n\n22 \n\n \n\n \n\ndestaca devido a sua disponibilidade imediata e reserva praticamente ilimitada \n\n(MUSCHLER et al, 2004). \n\nA presen\u00e7a de um material de suporte \u00e9 indispens\u00e1vel quando se \n\nnecessita reconstruir um tecido \u00f3sseo adulto. Macroscopicamente ele vai \n\npermitir a manuten\u00e7\u00e3o do volume \u00f3sseo perdido e prevenir a invagina\u00e7\u00e3o de \n\nmassa muscular circunvizinha no defeito \u00f3sseo. Do ponto de vista tecidual, \n\neste material far\u00e1 o vigamento, servindo como uma matriz no qual novo tecido \n\nser\u00e1 formado. Em n\u00edvel celular obt\u00e9m-se uma superf\u00edcie na qual as c\u00e9lulas-\n\ntronco poder\u00e3o aderir-se, proliferar-se e diferenciar-se (POTIER; PETITE, \n\n2005). \n\nLobo et al (2011) utilizaram a biocer\u00e2mica Osteosynt\u00ae, na propor\u00e7\u00e3o de \n\n65% de hidroxiapatita e 35% de  beta-tric\u00e1lcio-fosfato, na forma de gr\u00e2nulos de \n\n40-60 micra, sobre a qual foram cultivadas c\u00e9lulas-tronco de polpa de dentes \n\ndec\u00edduos. O biomaterial nanoestruturado permitiu a ades\u00e3o das c\u00e9lulas-tronco \n\ne sua prolifera\u00e7\u00e3o in vitro. Uma revis\u00e3o sobre as propriedades dos materiais \n\nem rela\u00e7\u00e3o a osteoindutividade comprovou que ainda n\u00e3o se sabe como \n\nalgumas cer\u00e2micas de fosfato de c\u00e1lcio podem ser mais osteoindutivas que \n\noutras e como suas propriedades f\u00edsico-qu\u00edmicas influenciam esse processo\n \n\n(SAMAVEDI, WHITTINGTON, GOLDSTEIN, 2009). \n\nO biomaterial do estudo foi uma biocer\u00e2mica fosfac\u00e1lcica bif\u00e1sica nano-\n\nmicro-macro porosa de hidroxiapatita beta-tric\u00e1lcio-fosfato com caracter\u00edsticas \n\ne propriedades f\u00edsico-qu\u00edmicas semelhantes \u00e0 matriz mineral do tecido \u00f3sseo. \n\nEra composto principalmente de subst\u00e2ncias fosfac\u00e1lcicas mais est\u00e1veis com \n\narquitetura porosa intercomunicantes e resist\u00eancia mec\u00e2nica necess\u00e1ria, sendo \n\nsubstitu\u00edda naturalmente pelo organismo no processo de reabsor\u00e7\u00e3o \u00f3ssea. A \n\n\n\n23 \n\n \n\n \n\npropor\u00e7\u00e3o de HA \u00e9 60% e ?TPC \u00e9 40% com micro poros de 10 micra e o \n\ndi\u00e2metro dos poros intercomunicantes de at\u00e9 500 micra. Uma das grandes \n\nvantagens da biocer\u00e2mica Osteosynt\u00ae \u00e9 que podem ser confeccionadas pe\u00e7as \n\npara reconstru\u00e7\u00f5es feitas individualmente correspondendo ao formato exato do \n\ndefeito \u00f3sseo atrav\u00e9s de modelos prototipados de tomografias 3D (Figura 2). \n\n \n\n \nFigura 2 Pe\u00e7as prototipadas de ossos de diversas partes do corpo para \n\nreconstru\u00e7\u00e3o (PELEGRINE; MACEDO; COSMO, 2008). \n\n \n \n\nOs meios indutores atualmente s\u00e3o t\u00f3xicos ou de dif\u00edcil obten\u00e7\u00e3o como \n\nBMPs. Diante do exposto, o estudo em quest\u00e3o avaliou o potencial da \n\nbiocer\u00e2mica Osteosynt\u00ae como um poss\u00edvel indutor in situ na regenera\u00e7\u00e3o \n\n\u00f3ssea, pr\u00e1tico, de f\u00e1cil obten\u00e7\u00e3o, biocompat\u00edvel e est\u00e9ril, facilitando estudos \n\ncom osteoblastos. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n24 \n\n \n\n \n\n3. MATERIAIS E M\u00c9TODOS \n\n A pesquisa foi realizada como a seguir. \n\n3.1 Considera\u00e7\u00f5es \u00e9ticas \n\nAp\u00f3s a aprova\u00e7\u00e3o pelo Comit\u00ea de \u00c9tica em Pesquisa da Universidade \n\nFederal de Pernambuco:  \n\nCAAE-0133.0.172.000-09                                                                         \n\nRegistro CEP/CCS /UFPE N\u00ba 135/09 \n\n3.2 Localiza\u00e7\u00e3o do estudo \n\n           A fase experimental foi realizada no Laborat\u00f3rio de Biof\u00edsica das \n\nMembranas e C\u00e9lulas-Tronco do Departamento de Biof\u00edsica e Radiobiologia da \n\nUFPE, Recife PE. \n\n3.3 Tipo de estudo \n\n Foi realizada uma investiga\u00e7\u00e3o experimental em laborat\u00f3rio, do tipo \n\nqualitativa.  \n\n3.4 Tamanho da amostra \n\n      Foram utilizados oito amostras da biocer\u00e2mica  fosfac\u00e1lcica bif\u00e1sica nano-\n\nmicro-macro porosa  de hidroxiapatita beta-tric\u00e1lcio-fosfato Osteosynt\u00ae densa \n\npara associa\u00e7\u00e3o com c\u00e9lulas-tronco de cord\u00e3o umbilical humano cultivadas no \n\nLaborat\u00f3rio de Biof\u00edsica das Membranas e C\u00e9lulas-Tronco do Departamento de \n\nBiof\u00edsica e Radiobiologia da UFPE. \n\n  3.5 Obten\u00e7\u00e3o e cultura de c\u00e9lulas-tronco \n\n Para obter e cultivar as c\u00e9lulas-tronco foram realizados os \n\nprocedimentos a seguir:  \n\n3.5.1. Coleta de cord\u00e3o umbilical humano. \n\n\n\n25 \n\n \n\n \n\n          As c\u00e9lulas-tronco mesenquimais foram isoladas de cord\u00e3o umbilical \n\nhumano de partos ces\u00e1reos realizados no Hospital De \u00c1vila sendo o termo de \n\nconsentimento livre e esclarecido em anexo, assinado pelas m\u00e3es doadoras \n\nantes da coleta. Os cord\u00f5es foram coletados em um recipiente est\u00e9ril contendo \n\nsolu\u00e7\u00e3o de EDTA (2 mM) em cloreto de s\u00f3dio a 0,9%, antibi\u00f3ticos\u2013penicilina \n\n(150 U/ml) e estreptomicina (150 \u00b5g/mL) e anfotericina (5 mg/ml) e foram \n\nprocessados no per\u00edodo de at\u00e9 6 horas ap\u00f3s o parto no Laborat\u00f3rio de Biof\u00edsica \n\ndas Membranas e C\u00e9lulas-Tronco do Departamento de Biof\u00edsica e \n\nRadiobiologia da UFPE. \n\n3.5.2 Isolamento e cultivo das c\u00e9lulas-tronco mesenquimais (MSCs) \n\n A metodologia necess\u00e1ria e eficiente para o isolamento e cultivo das \n\nMSCs foi bem estabelecida pela equipe do Laborat\u00f3rio de Biof\u00edsica das \n\nMembranas e C\u00e9lulas-Tronco do Departamento de Biof\u00edsica e Radiobiologia da \n\nUFPE (MIRANDA-OLIVEIRA, et al. 2009; MALAGUETA-VIEIRA, et al. 2010; \n\nALBERTIM, 2010). As art\u00e9rias e veias foram retiradas do cord\u00e3o umbilical e \n\ndescartadas, o tecido contendo a gel\u00e9ia de Wharton foi seccionado em \n\nfragmentos com cerca de tr\u00eas cm (Figura 2). \n\n\n\n26 \n\n \n\n \n\n                                                                                  \n\nFigura 3. Foto de cord\u00e3o umbilical humano na etapa inicial do processo de isolamento das \n\nc\u00e9lulas-tronco mesenquimais   \n\n  Estes fragmentos de tecidos foram depositados em garrafas de cultura, \n\ncontendo meio Dulbecco's Modified Eagle Medium (DMEM) baixa glicose \n\n(Gibco) suplementado com 15% soro fetal bovino  (SFB), LGC Biotecnologia, \n\n20% fator de crescimento (F12, Gibco), antibi\u00f3ticos\u2013penicilina (150 U/ml), \n\nestreptomicina (150 \u00b5g/mL) e anfotericina (5 mg/ml). As garrafas foram \n\narmazenadas na estufa a 37 \u00baC, 80% umidade e 5% CO2. As c\u00e9lulas migraram \n\nespontaneamente do tecido, aderiram-se ao pl\u00e1stico das garrafas e formaram \n\n\u201cmonocamadas\u201d ap\u00f3s 15 e 21 dias. \n\n3.5.3. Imunofenotipagem das CTMs \n\n        As c\u00e9lulas obtiveram a confirma\u00e7\u00e3o da linhagem mesenquimal  atrav\u00e9s da \n\nrealiza\u00e7\u00e3o da citometria de fluxo  (FACScalibur BD\n\u00ae \n\n), sendo utilizados \n\nanticorpos monoclonais, ou seja marcadores de c\u00e9lulas mesenquimais (CD 29, \n\nCD 44 E CD 90) e marcadores de c\u00e9lulas das linhagens endotelial e \n\nhematopoi\u00e9tica (CD 31, CD 34 e CD 45), que reconhecem ant\u00edgenos \n\nespec\u00edficos da membrana das c\u00e9lulas e que foram conjugados com mol\u00e9culas \n\nfluorescentes (FITC).  \n\n\n\n27 \n\n \n\n \n\n3.5.4. Cultivo das c\u00e9lulas-tronco com a biocer\u00e2mica \n\n Em uma capela de fluxo laminar seccionamos a biocer\u00e2mica com um \n\nmotor Surgic XT NSK com pe\u00e7a de m\u00e3o Kavo e disco de a\u00e7o em um fragmento \n\nmaior, cinco fragmentos menores e fragmentos diminutos com p\u00f3 (Figura 4). \n\n \n\nFigura 4. Capela de fluxo laminar onde o botton da biocer\u00e2mica foi seccionado com o motor \n\nSurgic XT NSK e pe\u00e7a de m\u00e3o Kavo acoplado com disco de a\u00e7o. \n\n Em uma placa de 96 po\u00e7os colocamos o meio DMEM baixa glicose \n\n(Gibco) suplementado com 15% soro fetal bovino (SFB, LGC Biotecnologia) e \n\nantibi\u00f3ticos\u2013penicilina (150 U/ml) e estreptomicina (150 \u00b5g/mL) e anfotericina (5 \n\nmg/ml) em 09 po\u00e7os com o biomaterial e as c\u00e9lulas da seguinte forma: \n\n1. Po\u00e7o A1- Fragmento maior com c\u00e9lulas-tronco \n\n2. Po\u00e7os- F3, F4, F5, F6 e F7- Fragmentos menores com c\u00e9lulas-tronco \n\n3. Po\u00e7os G8 e G9- P\u00f3 e fragmentos diminutos com c\u00e9lulas-tronco \n\n4. Po\u00e7o G10- Controle s\u00f3 com c\u00e9lulas-tronco sem o biomaterial (Figura 5)  \n\n\n\n28 \n\n \n\n \n\n \n\nFigura 5. Placa de 96 po\u00e7os contendo amostras da biocer\u00e2mica, meio e c\u00e9lulas-tronco \n\nmesenquimais de cord\u00e3o umbilical humano. \n\n A placa foi mantida em estufa a 37\u00ba por 21 dias, realizando as trocas do \n\nmeio de cultura a cada 03 dias.  \n\n3.5.5. Avalia\u00e7\u00e3o das caracter\u00edsticas morfol\u00f3gicas das CTMs cultivadas em \n\ncontato com a biocer\u00e2mica comercial Osteosynt\u00ae \n\n        As culturas de c\u00e9lulas foram acompanhadas semanalmente atrav\u00e9s de \n\nsistema de v\u00eddeo-microscopia (LEICA) para verifica\u00e7\u00e3o das caracter\u00edsticas \n\nmorfol\u00f3gicas e analise das condi\u00e7\u00f5es do cultivo (Figura 6). \n\n \n\nFigura 6. Avalia\u00e7\u00e3o semanal da cultura com o microsc\u00f3pio Leica. \n\n\n\n29 \n\n \n\n \n\n3.5.6. An\u00e1lise das c\u00e9lulas diferenciadas \n\n      As c\u00e9lulas submetidas \u00e0 indu\u00e7\u00e3o e controle foram lavadas com PBS, \n\nfixadas em formalde\u00eddo a 4% durante 20 minutos, lavadas com \u00e1gua \n\ndeionizada e expostas a 2% de vermelho de alizarina durante 15 minutos. \n\nForam lavadas v\u00e1rias vezes com \u00e1gua deionizada, retirando o excesso de \n\ncorante e examinadas ao microsc\u00f3pio invertido (LEICA DMIL; Leica \n\nMicrosystems GmbH, Bensheim, Alemanha). As imagens foram adquiridas com \n\numa c\u00e2mera de v\u00eddeo CCD (Motic 2000; Quimis Diadema, SP, Brasil) acoplada \n\nao microsc\u00f3pio (Figura 7).  \n\n \n\nFigura 7. C\u00e9lulas examinadas ao microsc\u00f3pio invertido (LEICA DMIL; Leica Microsystems \n\nGmbH, Bensheim, Alemanha) e realiza\u00e7\u00e3o da capta\u00e7\u00e3o das imagens com uma c\u00e2mera de \n\nv\u00eddeo CCD (Motic 2000; Quimis Diadema, SP, Brasil) acoplada ao microsc\u00f3pio.  \n\n \n\n4.RESULTADOS E DISCUSS\u00c3O \n\nDe acordo com os dados obtidos observamos que: \n\n 4.1 Nas garrafas de cultura de CTMs, ap\u00f3s 72 horas, apresentaram \n\ncol\u00f4nias de c\u00e9lulas com morfologia fibroblast\u00f3ide, onde sua an\u00e1lise morfol\u00f3gica \n\n\u00e9 de grande import\u00e2ncia, visto que o padr\u00e3o de crescimento destas c\u00e9lulas \u00e9 \n\ndescrita como fibroblast-like \n[19]\n\n. A forma\u00e7\u00e3o da monocamada ocorreu em torno \n\n\n\n30 \n\n \n\n \n\nde uma semana de cultivo in vitro, onde visualizamos tapete celular com \n\nalgumas \u00e1reas abertas a serem posteriormente preenchidas (Figura 8). \n\n \nFigura 8. Fotomicrografia de c\u00e9lulas-tronco mesenquimais de cord\u00e3o umbilical humano \ncultivadas in vitro, realizada com aux\u00edlio de microsc\u00f3pio invertido de contraste de fase. \nObserva-se forma\u00e7\u00e3o de monocamada com t\u00edpicas c\u00e9lulas fibroblast\u00f3ide. Escala de barra = 50 \n\u00b5m. \n\n As c\u00e9lulas aderentes foram cultivadas at\u00e9 alcan\u00e7arem uma conflu\u00eancia \n\nde 80-90%, quando foi procedida a realiza\u00e7\u00e3o da 1\u00aa passagem ou seja, as \n\nc\u00e9lulas foram tripsinizadas (5mg de tripsina/mL PBS, Sigma), ressuspendidas \n\nem meio de cultura, coradas com Azul de Trypan (0,2%, Sigma), contadas em \n\nC\u00e2mara de Neubauer e acondicionadas em garrafas de 75 cm2 (Cellstar) para \n\nexpans\u00e3o.          \n\n4.2. An\u00e1lise da imunofenotipagem das CTMs \n\nA an\u00e1lise imunofenot\u00edpica deste estudo (Figura 9) revelou express\u00e3o \n\npositiva para marcadores moleculares de superf\u00edcie como CD 44 (receptor de \n\nhialuronato), CD 29 (mol\u00e9cula de ades\u00e3o da superfam\u00edlia das Integrinas \u2013 VLA \n\nbeta) e CD 90 (Thy-1). Al\u00e9m do que, foi confirmada express\u00e3o negativa para \n\nmarcadores t\u00edpicos de linhagens hematopoi\u00e9ticas e endoteliais, como CD 31 \n\n(PECAM-1: mol\u00e9cula de ades\u00e3o plaquet\u00e1ria), CD 34 (receptor de c\u00e9lulas \n\nendoteliais) e CD 45 (presentes em todas as c\u00e9lulas hematopoi\u00e9ticas); \n\nconfirmando-se assim o que \u00e9 mencionado na literatura. \n\n\n\n31 \n\n \n\n \n\n \n\nFigura 9. An\u00e1lise por citometria de fluxo da express\u00e3o de marcadores de superf\u00edcie de c\u00e9lulas-\ntronco mesenquimais do cord\u00e3o umbilical humano. Os dados mostrados s\u00e3o do fen\u00f3tipo de \nc\u00e9lulas analisadas no final da terceira passagem. O controle \u00e9 mostrado em vermelho. \n\nTodas as c\u00e9lulas do organismo apresentam um perfil de marcadores de \n\nsuperf\u00edcie que caracterizam a singularidade biol\u00f3gica e a marca das c\u00e9lulas \n\nque os cont\u00eam \n[20]\n\n. Apesar da grande quantidade de marcadores positivos \n\ndescritos na literatura n\u00e3o h\u00e1 para as CTMs um marcador positivo definido e \n\ndefinitivo. Sendo sua caracteriza\u00e7\u00e3o estabelecida pela identifica\u00e7\u00e3o de uma \n\ncombina\u00e7\u00e3o de marcadores espec\u00edficos e n\u00e3o espec\u00edficos \n[21,22, e 23]\n\n. \n\nPara a Sociedade Internacional de Terapia Celular (SITC) as CTMs s\u00e3o \n\nnegativas para a express\u00e3o dos marcadores CD34, CD45 e CD14; crescem \n\naderidas ao substrato, s\u00e3o cultiv\u00e1veis por longos per\u00edodos e capazes de se \n\ndiferenciar em pelo menos duas linhagens celulares. H\u00e1 na literatura, um \n\nconsenso de que as CTMs expressam n\u00edveis vari\u00e1veis de CD44 e tamb\u00e9m t\u00eam \n\nexpress\u00e3o positiva para a mol\u00e9cula de ades\u00e3o CD29 \n[24]\n\n. \n\n4.3. Morfologia das CTMs durante o processo de diferencia\u00e7\u00e3o osteog\u00eanica \n\nsobre a Biocer\u00e2mica   \n\nA morfologia das CTMs em estudo condiz com o achado de que a \n\nestimula\u00e7\u00e3o das mesmas pela presen\u00e7a do biomaterial (cer\u00e2mica em pequenos \n\nblocos ou diminutos fragmentos) com capacidade de diferencia\u00e7\u00e3o osteog\u00eanica \n\nfoi capaz de produzir c\u00e9lulas possivelmente secretoras (Figura 10). \n\n\n\n32 \n\n \n\n \n\n \nFigura 10. Fotomicrografia da biocer\u00e2mica fosfoc\u00e1lcica bif\u00e1sica porosa de HA-?TCP em \nassocia\u00e7\u00e3o com c\u00e9lulas-tronco mesenquimais de cord\u00e3o umbilical, realizadas com aux\u00edlio de \nmicrosc\u00f3pio invertido de contraste de fase. C\u00e9lulas fibroblast\u00f3ide s\u00e3o observadas pr\u00f3ximas ao \n\u00fanico bloco de cer\u00e2mica (estrela). Escala de barra = 100 \u00b5m. \n \n\nA caracter\u00edstica marcante neste processo foi a aglomera\u00e7\u00e3o celular e poder \n\nobservar a disposi\u00e7\u00e3o das c\u00e9lulas em cadeias, al\u00e9m de uma morfologia \n\nmarcada pela presen\u00e7a de concre\u00e7\u00f5es de c\u00e1lcio no interior das mesmas \n\nrevelado pela citoqu\u00edmica coradas com o vermelho de Alizarina (Figura 11). \n\nQuanto mais pr\u00f3ximo dos fragmentos mais as c\u00e9lulas foram induzidas \u00e0 \n\ndiferencia\u00e7\u00e3o e apresentaram mais dep\u00f3sitos de c\u00e1lcio, quando comparadas \n\n\u00e0quelas situadas mais distantes. Independente da localiza\u00e7\u00e3o, a cultura como \n\num todo foi induzida a diferencia\u00e7\u00e3o osteog\u00eanica em fun\u00e7\u00e3o do contato com a \n\nbiocer\u00e2mica estudada (Figuras 12). \n\n\n\n33 \n\n \n\n \n\n \nFigura 11. Fotomicrografia de c\u00e9lulas-tronco mesenquimais de cord\u00e3o umbilical humano \ncultivadas em associa\u00e7\u00e3o com a biocer\u00e2mica fosfoc\u00e1lcica bif\u00e1sica porosa de HA-?TCP, em \ndiferencia\u00e7\u00e3o osteog\u00eanica coradas com solu\u00e7\u00e3o vermelho de Alizarina e visualizadas com \naux\u00edlio de microsc\u00f3pio invertido de contraste de fase: Detecta-se dep\u00f3sitos de c\u00e1lcio nas \nc\u00e9lulas diferenciadas (setas brancas); dep\u00f3sitos de c\u00e1lcio intracitoplasm\u00e1ticos s\u00e3o observados \ncorados em vermelho. Escala de barra = 50 \u00b5m. \n\n \nFigura 12. Fotomicrografia da morfologia de c\u00e9lulas-tronco mesenquimais de cord\u00e3o umbilical \nhumano induzidas \u00e0 diferencia\u00e7\u00e3o osteog\u00eanica pela biocer\u00e2mica fosfoc\u00e1lcica bif\u00e1sica porosa \nde HA-?TCP (fragmentos castanhos). Culturas avaliadas com aux\u00edlio de microsc\u00f3pio invertido: \nsem contraste de fase (A) e com contraste de fase (B). Escala de barra = 100 \u00b5m. \n \n\nNa engenharia tecidual, as CTMs s\u00e3o as c\u00e9lulas de escolha para \n\npesquisas com o objetivo de reparar defeitos teciduais. As linhas de pesquisas \n\navan\u00e7am na cria\u00e7\u00e3o in vitro de tecidos que possam aumentar a osteog\u00eanese \n\nno s\u00edtio desses defeitos ou no transplante direto das CTMs em scafolds, devido \n\nao papel dessas c\u00e9lulas na forma\u00e7\u00e3o da matriz extracelular\n25\n\n. Analisamos o \n\npotencial de diferencia\u00e7\u00e3o em osteoblastos das CTMs sobre a biocer\u00e2mica \n\nfosfoc\u00e1lcica bif\u00e1sica porosa de HA-?TCP durante tr\u00eas semanas de indu\u00e7\u00e3o \n\n\n\n34 \n\n \n\n \n\nosteog\u00eanica e podemos constatar que a biocer\u00e2mica em quest\u00e3o sustentou a \n\ndiferencia\u00e7\u00e3o sendo evidenciada pela marca\u00e7\u00e3o dos dep\u00f3sitos de c\u00e1lcio \n\nintracelulares com o vermelho de alizarina, em todas as amostras. \n\n \n\n5 CONCLUS\u00d5ES \n\n            A biocer\u00e2mica comportou-se como um indutor pr\u00e1tico, eficaz e \n\nbiocompat\u00edvel, promovendo a diferencia\u00e7\u00e3o osteog\u00eanica e mantendo-se est\u00e1vel \n\ndurante o experimento, podendo ser usado em pesquisas com c\u00e9lulas-tronco \n\nde cord\u00e3o umbilical humano para osteoindu\u00e7\u00e3o. \n\n As c\u00e9lulas-tronco foram induzidas a diferencia\u00e7\u00e3o osteog\u00eanica em \n\nfun\u00e7\u00e3o do contato com a biocer\u00e2mica estudada e constatamos que a mesma \n\nsustentou a diferencia\u00e7\u00e3o evidenciada pela marca\u00e7\u00e3o dos dep\u00f3sitos de c\u00e1lcio \n\nintracelulares com o vermelho de alizarina. \n\n A cultura foi induzida a diferencia\u00e7\u00e3o osteog\u00eanica em todas as amostras \n\ndo biomaterial, demonstrando em an\u00e1lises iniciais que a associa\u00e7\u00e3o da \n\nbiocer\u00e2mica Osteosynt\u00ae \u00e0 c\u00e9lula-tronco de cord\u00e3o umbilical humano sugere \n\napresentar um \u00f3timo potencial para o desenvolvimento de novas t\u00e9cnicas \n\nterap\u00eauticas no tratamento de grandes perdas \u00f3sseas. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n35 \n\n \n\n \n\nREFER\u00caNCIAS \n\n \n\n1. Wei X, et al. Hydroxyapatite microspheres: A novel bioactive and \n\nosteoconductive carrier for controlled release of bone morphogenetic \n\nprotein-2 in bone regeneration. Acta Biomaterialia 2013, 8374- 8873. \n\n2. Coelho APG.  Evaluation of bone response to various anorganic bovine \n\nbone xenografts: an experimental calvaria defect study. International \n\nJournal of Oral and Maxillofacial Surgery, 2013, 298- 301. \n\n3. Rodrigues PL, et al. Efeito da adi\u00e7\u00e3o de alumina nas propriedades \n\nf\u00edsicas e mec\u00e2nicas do ?-fosfato tric\u00e1lcico. Cer\u00e2mica, 2012, 368-373 \n\n4.  Mori M, et al. Biological implications of growth factors in bone \n\nremodeling following fracture, surgical resection and bonegrafting. Part 1: \n\nTransforming growth factors, bone morphogenetic proteins and related \n\nfactors. Asian Journal of Oral and Maxillofacial Surgery, p. 117-125, \n\n2010. \n\n5. Guerrero J, et al. Cell interactions between human progenitor-derived \n\nendothelial cells and human mesenchymal stem cells in a three-\n\ndimensional macroporous polysaccharide-based scaffold promote \n\nosteogenesis. Acta Materialia, 2013, 189-204.   \n\n6. Oliveira AP. Estudo retrospectivo de 09 casos de enxerto \u00f3sseo \n\nhal\u00f3geno. Monografia apresentada \u00e0 Universidade Federal de \n\nPernambuco para obten\u00e7\u00e3o do t\u00edtulo de Especialista em Cirurgia Buco \n\nMaxilo Facial, 2008. \n\n7. Pellegrine AA, Macedo LG, Cosmo LA. Transplantes \u00f3sseos na \n\nodontologia. Nova Odessa: Napole\u00e3o, 2008. 272 p. \n\nhttp://www.sciencedirect.com/science/article/pii/S174270611300278X\nhttp://www.sciencedirect.com/science/article/pii/S0915699210000476\nhttp://www.sciencedirect.com/science/article/pii/S1742706113002742\nhttp://www.sciencedirect.com/science/article/pii/S1742706113002742\nhttp://www.sciencedirect.com/science/article/pii/S1742706113002742\nhttp://www.sciencedirect.com/science/article/pii/S1742706113002742\n\n\n36 \n\n \n\n \n\n8. Zerbo IR, et al. Histology of human alveolar bone regeneration with a \n\nporous tricalcium phos-phate. A report of two cases. Clin Oral Impl Res, \n\n2001, 379-384. \n\n9. Misch CE. Implantes Dent\u00e1rios Contempor\u00e2neos.  2a. S\u00e3o Paulo: \n\nSantos, 2006. 685 p. \n\n10. Schwarz JM, et al. Observing metabolic functions at the genoma scale. \n\nGenome Biology, 2007, p. 123-126. \n\n11. Silveira C D, et al. Stemcell therapy for cardiology: a new path to \n\nhumanity and a new care for nurses - a case report. Online Brazilian \n\nJournal of Nursing [online] 2006 Apr; v.4 n.1, Dispon\u00edvel em: \n\nwww.uff.br/nepae/objn401silveiraetal.htm. Acesso em 21 de maio de \n\n2012. \n\n12. Peres CM, Curi  . Como cultivar c\u00e9lulas. 1  ed.  io de  aneiro, \n\nGuanabara Koogan, 2005. \n\n13. Muschler G, Nakamoto C, Griffith, LG. Engineering principles of clinical \n\ncell-based tissue engineering. Journal Bone Joint Surgery Am, Boston, \n\n2004,p.1541-57. \n\n14. Lobo SE. Associa\u00e7\u00e3o de c\u00e9lulas-tronco da polpa dental a biocer\u00e2mica de \n\nfosfato de c\u00e1lcio na bioengenharia do tecido \u00f3sseo. Tese apresentada a \n\nUniversidade Federal de S\u00e3o Paulo para obten\u00e7\u00e3o do T\u00edtulo de Doutora \n\nem Biologia Estrutural e Funcional, 2011. \n\n15. Samavedi S, Whittington AR, Goldstein AS. Calcium phosphate ceramics \n\nin bone tissue engineering: A review of properties and their influence on \n\ncell behavior. Acta Biomaterialia, USA, 2009, p.8037-8045. Dispon\u00edvel \n\nem:&lt;http://dx.doi.org/10.1016/j.actbio.>. Acesso em: 14 jun. 2013. \n\n\n\n37 \n\n \n\n \n\n16. Miranda-Oliveira AL, et al. Isolamento r\u00e1pido e eficaz de c\u00e9lulas-tronco \n\nmesenquimais de cord\u00e3o umbilical. Recife,PE. In: Simp\u00f3sio Internacional \n\nDe Terapias Avan\u00e7adas E C\u00e9lulas-tronco, 2009. \n\n17. Malagueta-Vieira LLL, et al. Estudo dos canais i\u00f4nicos nas c\u00e9lulas-tronco \n\nmesenquimais de cord\u00e3o umbilical humano. Gramado, RS. In: V \n\nCongresso Brasileiro C\u00e9lulas- Tronco e Terapia Celular, 2010. \n\n18. Albertim GJB. Estudo da participa\u00e7\u00e3o de canais de pot\u00e1ssio no processo \n\nde RVD das c\u00e9lulas-tronco mesenquimais obtidas do cord\u00e3o umbilical \n\nhumano. Gramado, RS. In: V Congresso Brasileiro C\u00e9lulas- Tronco e \n\nTerapia Celular, 2010. \n\n19. Bittencourt RAC, et al. Isolamento e cultivo de c\u00e9lulas-tronco \n\nmesenquimais da medula \u00f3ssea. Acta Ortop. Bras. 2006, p. 141-146. \n\n20. Covas, DT. C\u00e9lulas-tronco mesenquimais. In: Zago MA, Covas DT. \n\nC\u00e9lulas-tronco: a nova fronteira da medicina. S\u00e3o Paulo: Atheneu, 2006. \n\np. 35-48. \n\n21. Meirelles LS, et al. Mesenchymal stem cells reside in virtually all post-\n\nnatal organs and tissues. Journal of Cell Science, 2006, p. 2204-2213. \n\n22. Meirelles LS, et al. In search of the in vivo identity of mesenchymal stem \n\ncells. Stem Cells, 2008, p. 2287-2299. \n\n23. Meirelles, LS, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in \n\nthe therapeutic properties of mesenchymal stem cells. Cytokine Growth \n\nFactor Rev.,2009, p. 419-427.  \n\n24. Bydlowski SP, et al. Caracter\u00edsticas biol\u00f3gicas das c\u00e9lulas-tronco \n\nmesenquimais. Rev. Bras. Hematol. Hemoter., 2009, p. 25-35. \n\n25. Caplan AI. All MSCs are pericytes? Cell Stem Cell,2008, p.229-230. \n\n \n\n\n\n38 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAP\u00caNDICE \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n39 \n\n \n\n \n\nTERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO \n \n\nResolu\u00e7\u00e3o n\u00ba 196/96 \u2013 Conselho Nacional de Sa\u00fade \n \nO(a) Sr(a)  foi selecionado(a) e est\u00e1 sendo convidado(a) para participar da \npesquisa intitulada: \"AVALIA\u00c7\u00c3O DA ASSOCIA\u00c7\u00c3O DE C\u00c9LULAS-TRONCO \nMESENQUIMAIS DE CORD\u00c3O UMBILICAL HUMANO \u00c0 UMA BIOCER\u00c2MICA \nDE FOSFATO DE C\u00c1LCIO NA BIOENGENHARIA DO TECIDO \u00d3SSEO\", que \nser\u00e1 realizada pela Dra Ana Patr\u00edcia de Oliveira Souza no Laborat\u00f3rio de \nCultura de C\u00e9lulas do Departamento de Biof\u00edsica e Radiobiologia - CCB da \nUFPE sob Co-orienta\u00e7\u00e3o da  Prof\n\na\n Dr\n\na\n M\u00e1rcia Bezerra da Silva(Dept\n\no\n de \n\nBiof\u00edsica e Radiobiologia-CCB/UFPE) e Orienta\u00e7\u00e3o da Prof\na\n Dr\n\na\n Alessandra de \n\nAlbuquerque Tavares de Carvalho (Dept\no\n de Odontologia-CCS/UFPE) \n\n Justificativa e objetivos:  Atrav\u00e9s deste estudo avaliaremos o \ncomportamento  das c\u00e9lulas-tronco de cord\u00e3o umbilical humano frente a um \nbiomaterial a base de hidroxiapatita e beta tric\u00e1lcio fosfato, cujo objetivo ser\u00e1 \ndiferenciar as c\u00e9lulas em osteoblastos. \nInforma\u00e7\u00f5es: \nProcedimentos: No dia do seu parto a parte do cord\u00e3o umbilical do seu filho \nque seria desprezado e posteriormente incinerado ser\u00e1 colhido por mim em \nrecipiente est\u00e9ril e trazido para o laborat\u00f3rio para ser processado em at\u00e9 06 \nhoras. Ser\u00e1 retirada uma parte (a gel\u00e9ia de Warthon) e tratada para retirar as \nc\u00e9lulas-tronco mesenquimais(CTMs) que depois ser\u00e1 colocada em por\u00e7\u00f5es de \numa biocer\u00e2mica para avaliar como ser\u00e1 a diferencia\u00e7\u00e3o das  CTMs em \nosteoblastos. \nForma de acompanhamento e assist\u00eancia: Os pesquisadores estar\u00e3o \u00e0 \ndisposi\u00e7\u00e3o para quaisquer esclarecimentos adicionais pessoalmente, por fone \nou email (modo de contato abaixo). \nGarantias:  \nGarantia de esclarecimentos: Os pesquisadores esclarecer\u00e3o os volunt\u00e1rios \nquanto a todos os aspectos da pesquisa, antes, durante e depois da mesma.   \nLiberdade de recusa a participa\u00e7\u00e3o: Sua participa\u00e7\u00e3o \u00e9  volunt\u00e1ria, isto \u00e9, a \nqualquer momento voc\u00ea pode  recusar-se  a participar em qualquer fase da \nmesma ou de retirar seu consentimento, sem qualquer penaliza\u00e7\u00e3o ou preju\u00edso. \nSigilo: Seus dados pessoais ser\u00e3o mantidos em sigilo.  \n \nRessarcimento e indeniza\u00e7\u00e3o: N\u00e3o h\u00e1 gastos previstos pela sua participa\u00e7\u00e3o \nna pesquisa portanto n\u00e3o h\u00e1 previs\u00e3o de ressarcimento. N\u00e3o h\u00e1 riscos \nprevis\u00edveis pela sua participa\u00e7\u00e3o na pesquisa portanto n\u00e3oh\u00e1 previs\u00e3o de \nindeniza\u00e7\u00e3o. O benef\u00edcio  relacionado \u00e0 sua participa\u00e7\u00e3o ser\u00e1 de aumentar o \nconhecimento cient\u00edfico para na \u00e1rea de bioengenharia de tecido \u00f3sseo. \nA Sra receber\u00e1 uma c\u00f3pia do termo de consentimento livre e esclarecido onde \nconsta o  celular/e-mail  do pesquisador respons\u00e1vel, e demais membros da \nequipe, podendo tirar as suas d\u00favidas sobre o projeto e sua participa\u00e7\u00e3o, agora \nou a qualquer momento. Desde j\u00e1 agradecemos! \nPara contato com os pesquisadores: Dra. Ana Patr\u00edcia de Oliveira Souza \n(oapatricia@hotmail.com), Fone: (81) 91038449 (81) 30884310 e Prof\n\na\n Dr\n\na\n \n\nAlessandra de Albuquerque Tavares de Carvalho (at.carvalho@uol.com.br) Av. \nProf. Morais R\u00eago, 1235- Cidade Universit\u00e1ria. Recife, PE-Brasil, CEP: 50.670-\n901 Fone: (81) 2126-8817. Em caso de d\u00favidas quanto aos seus direitos como \n\n\n\n40 \n\n \n\n \n\nvolunt\u00e1rio de pesquisa entre em contato com o Comit\u00ea de \u00c9tica em Pesquisa  \nda UFPE: Av. Prof. Morais R\u00eago, 1235- Cidade Universit\u00e1ria. Recife, PE-Brasil, \nCEP: 50.670-901 Fone: 21268588 (cepccs@ufpe.br). \nEu,........................................................................................................................., \nconcordo em participar da pesquisa intitulada \"AVALIA\u00c7\u00c3O DA ASSOCIA\u00c7\u00c3O \nDE C\u00c9LULAS-TRONCO MESENQUIMAIS DE CORD\u00c3O UMBILICAL \nHUMANO \u00c0 UMA BIOCER\u00c2MICA DE FOSFATO DE C\u00c1LCIO NA \nBIOENGENHARIA DO TECIDO \u00d3SSEO\" \nDeclaro estar ciente do inteiro teor deste TERMO DE CONSENTIMENTO e \nestou de acordo em participar do estudo proposto, sabendo que dele poderei \ndesistir a qualquer momento, sem sofrer qualquer puni\u00e7\u00e3o ou constrangimento. \n............................................................................................................................. \n(volunt\u00e1rio) \n............................................................................................................................. \n(pesquisador) \n............................................................................................................................... \n(testemunha) \n \n \nRecife, ____ de _______________ de 20___. \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n41 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nANEXO \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n42 \n\n \n\n \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 1 \n\nACTA MATERIALIA \nPublished on behalf of Acta Materialia, Inc. \n\nAUTHOR INFORMATION PACK \n\nTABLE OF CONTENTS \n. \n\nXXX \n. \n\n\u2022 Description \n\u2022 Audience \n\u2022 Impact Factor \n\u2022 Abstracting and Indexing \n\u2022 Editorial Board \n\u2022 Guide for Authors \np.1 \np.1 \np.1 \np.2 \np.2 \np.4 \nISSN: 1359-6454 \n\nDESCRIPTION \n. \n\nActa Materialia provides a forum for publishing full-length, original papers and \n\ncommissioned \n\noverviews which advance the in-depth understanding of the relationship between \n\nthe processing, \nthe structure and the properties of inorganic materials. Papers which have a high \n\nimpact potential \n\nare sought. The structure encompasses atomic and molecular arrangements, \n\nchemical and electronic \nstructures, and microstructure. Emphasis is on either the mechanical or functional \n\nbehavior of \n\ninorganic solids at all length scales down to nanostructures. \n\nThe following aspects of the science and engineering of inorganic materials are of \n\nparticular interest: \n\n(i) Cutting-edge experiments and theory as they relate to the understanding of the \n\nproperties, \n\n(ii) Simulation and modeling preferably combined with experimentation specifically \n\nas they relate to \n\nthe understanding of the properties, \n\n(iii) Elucidation of the mechanisms involved in the synthesis and processing of \n\nmaterials specifically \n\nas they relate to the understanding of the properties,and \n\n(iv) Characterization of the structure and chemistry of materials specifically as it \n\nrelates to the \n\nunderstanding of the properties. \nShort communications and comments to papers published in Acta Materialia may be \n\nsubmitted to \n\nScripta Materialia. \nBenefits to authors \n\nWe also provide many author benefits, such as free PDFs, a liberal copyright policy, \n\nspecial discounts \n\non Elsevier publications and much more. Please click here for more information on \n\nour author services. \n\nPlease see our Guide for Authors for information on article submission. If you \n\nrequire any further \n\ninformation or help, please visit our support pages: http://support.elsevier.com \n\n\n\n43 \n\n \n\n \n\nAUDIENCE \n. \n\nMaterials Scientists and Engineers. \n\nIMPACT FACTOR \n. \n\n2012: 3.941 \u00a9 Thomson Reuters Journal Citation Reports 2013 \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 2 \n\nABSTRACTING AND INDEXING \n. \n\nApplied Mechanics Reviews \n\nCambridge Scientific Abstracts \n\nChemical Abstracts \n\nCurrent Contents \n\nEngineering Index \n\nINSPEC \n\nMaterials Science Citation Index \n\nMetals Abstracts \n\nPASCAL/CNRS \n\nScopus \n\nEDITORIAL BOARD \n. \n\nCoordinating Editor \n\nS. Mahajan, Dept. of Chemical Engineering and Materials Science, University of California at \n\nDavis, 1 Shields \nAvenue, Davis, CA 95616, USA, Tel: +1 530 752 5132, Fax: +1 530 752 1031, Email: \nactamat@ucdavis.edu \nEditorial Assistant: Becky Houston , Email: actamat@ucdavis.edu \nEditors \n\nG. Gottstein, Inst. f\u00fcr Metallkunde und Metallphysik, Rheinisch-Westf\u00e4lische Technische \n\nHochschule \nAachen (RWTH), Kopernikusstr. 14, D-52056 Aachen, Germany, Fax: +49-241-80-2-26-08, \n\nTelephone: \n+49-241-80-2-68-60 , Email: acta@imm.rwth-aachen.de \n\nEditorial Assistant: Norma Gottstein \nM. Harmer, Dept. of Materials Science &amp; Engineering, Lehigh University, 27 Memorial Drive \n\nWest, Bethlehem, \nPA. 18015, USA, Email: actamat@lehigh.edu \n\nEditorial Assistant: Elsie Hamel \nK. Hono, National Institute of Materials Science, 1-2-1 Sengen, 305-0047 Tsukuba, Japan, \n\nFax: 81-298-59-2701, \nTelephone: 81-298-59-2718, Email: acta@nims.go.jp \n\nEditorial Assistant: Huai Ying Fang \nS. Jin, Dept. of Materials Science and Engineering, Dept. of Mechanical &amp; Aerospace \n\nEngineering &amp; \nNanoengineering, University of California at San Diego (UCSD), 9500 Gilman Dr, La Jolla, CA \n92093, USA , Email: \n\nactamat@ucsd.edu \n\nEditorial Assistant: Michael Reiss \nR. Kirchheim, Inst. f\u00fcr Materialphysik, Georg-August Universit\u00e4t G\u00f6ttingen, Tammannstr. 1, \n\n37077 G\u00f6ttingen, \nGermany, Fax: +49-551-39-5000, Email: acta@uni-goettingen.de \n\nEditorial Assistant: Dorothea Kirchheim \nJ. Rickman, Dept. of Materials Science &amp; Engineering, Lehigh University, 27 Memorial Drive \n\nWest, Bethlehem, \nPA. 18015, USA, Telephone: +610-758-4236, Email: actamat@lehigh.edu \n\nEditorial Assistant: Elsie Hamel \nC.A. Schuh, Dept. of Materials Science and Engineering, Massachusetts Institute of \n\nTechnology (MIT), 77 \nMassachusetts Avenue, Cambridge, MA 02139, USA, Fax: +1-617-324-0052, Telephone: +1-\n617-452-2659, \n\nEmail: actamaterialia@mit.edu \n\nAssociate Editors: Professor Katharine M. Flores, Dr. Marc Legros, Professor David \n\nRodney \n\n\n\n44 \n\n \n\n \n\nR. Wagner, Institut Laue-Langevin, 6 rue Jules Horotwiz BP 156, 38042 Grenoble, France, \n\nFax: \n+33-476-961195, Email: acta@ill.fr \n\nEditorial Assistant: Margrit Wagner \nThe Board of Governors of Acta Materialia \nThe Board of Governors is constituted as follows: \nG. Gray, III, \n\nChair, Treasurer and Board Governor \nT.B. Massalski, \n\nExecutive Secretary and Board Governor \nA.J. Coury, \n\nBoard Governor \nY. Brechet, \n\nSoci\u00e9t\u00e9 Fran\u00e7aise de M\u00e9tallurgie et de Mat\u00e9riaux Representative Governor \nC. Hansson, \n\nThe Metallurgical Society of CIM (Canada) Representative Governor \nW. Kurz, \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 3 \n\nFEMS Representative Governor \nS. Mahajan, \n\nCoordinating Editor and Governor \nT. Ohji, ASM Governor \nG.B. Olson, ASM Governor \nD. Raabe, \n\nGerman Steel Institute (VDeh) Representative Governor \nS. Ramakrishna, \n\nASM Governor \nM. Singh, \n\nASM Governor \nG.W. Warren, \n\nTMS Governor \nK.S. Anseth, \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 4 \n\nGUIDE FOR AUTHORS \n. \n\nINTRODUCTION \nActa Materialia provides a forum for publishing full-length, original papers and \n\ncommissioned \n\noverviews which advance the in-depth understanding of the relationship between \n\nthe processing, \n\nthe structure and the properties of inorganic materials. Papers which have a high \n\nimpact potential \n\nare sought. The structure encompasses atomic and molecular arrangements, \n\nchemical and electronic \n\nstructures, and microstructure. Emphasis is on either the mechanical or functional \n\nbehavior of \n\ninorganic solids at all length scales down to nanostructures. \n\nThe following aspects of the science and engineering of inorganic materials are of \n\nparticular interest: \n\n(i) Cutting-edge experiments and theory as they relate to the understanding of the \n\nproperties, \n\n(ii) Simulation and modeling preferably combined with experimentation specifically \n\nas they relate to \n\nthe understanding of the properties, \n\n(iii) Elucidation of the mechanisms involved in the synthesis and processing of \n\nmaterials specifically \n\nas they relate to the understanding of the properties, and \n\n(iv) Characterization of the structure and chemistry of materials specifically as it \n\nrelates to the \n\nunderstanding of the properties. \n\n\n\n45 \n\n \n\n \n\nShort communications and comments to papers published in Acta Materialia may be \n\nsubmitted to \n\nScripta Materialia. \n\nBEFORE YOU BEGIN \nEthics in publishing \nFor information on Ethics in publishing and Ethical guidelines for journal publication \n\nsee \n\nhttp://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-\n\nauthors/ethics. \n\nConflict of interest \nAll authors are requested to disclose any actual or potential conflict of interest \n\nincluding any financial, \n\npersonal or other relationships with other people or organizations within three years \n\nof beginning the \n\nsubmitted work that could inappropriately influence, or be perceived to influence, \n\ntheir work. See \n\nalso http://www.elsevier.com/conflictsofinterest. Further information and an \n\nexample of a Conflict of \n\nInterest form can be found at: \n\nhttp://elsevier6.custhelp.com/app/answers/detail/a_id/286/p/7923/. \n\nSubmission declaration \nSubmission of an article implies that the work described has not been published \n\npreviously (except \n\nin the form of an abstract or as part of a published lecture or academic thesis or as \n\nan electronic \n\npreprint, see http://www.elsevier.com/postingpolicy), that it is not under \n\nconsideration for publication \n\nelsewhere, that its publication is approved by all authors and tacitly or explicitly by \n\nthe responsible \n\nauthorities where the work was carried out, and that, if accepted, it will not be \n\npublished elsewhere \n\nincluding electronically in the same form, in English or in any other language, \n\nwithout the written \n\nconsent of the copyright-holder. \n\nChanges to authorship \nThis policy concerns the addition, deletion, or rearrangement of author names in \n\nthe authorship of \n\naccepted manuscripts: \nBefore the accepted manuscript is published in an online issue: Requests to add or remove \n\nan author, \n\nor to rearrange the author names, must be sent to the Journal Manager from the \n\ncorresponding author \n\nof the accepted manuscript and must include: (a) the reason the name should be \n\nadded or removed, \n\nor the author names rearranged and (b) written confirmation (e-mail, fax, letter) \n\nfrom all authors that \n\nthey agree with the addition, removal or rearrangement. In the case of addition or \n\nremoval of authors, \n\nthis includes confirmation from the author being added or removed. Requests that \n\nare not sent by \n\nthe corresponding author will be forwarded by the Journal Manager to the \n\ncorresponding author, who \n\nmust follow the procedure as described above. Note that: (1) Journal Managers will \n\ninform the Journal \n\nEditors of any such requests and (2) publication of the accepted manuscript in an \n\nonline issue is \n\nsuspended until authorship has been agreed. \n\n\n\n46 \n\n \n\n \n\nAfter the accepted manuscript is published in an online issue: Any requests to add, delete, \n\nor rearrange \n\nauthor names in an article published in an online issue will follow the same policies \n\nas noted above \n\nand result in a corrigendum. \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 5 \n\nCopyright \nUpon acceptance of an article, authors will be asked to complete a 'Journal \n\nPublishing Agreement' (for \n\nmore information on this and copyright see http://www.elsevier.com/copyright). \n\nAcceptance of the \n\nagreement will ensure the widest possible dissemination of information. An e-mail \n\nwill be sent to \n\nthe corresponding author confirming receipt of the manuscript together with a \n\n'Journal Publishing \n\nAgreement' form or a link to the online version of this agreement. \n\nSubscribers may reproduce tables of contents or prepare lists of articles including \n\nabstracts for internal \n\ncirculation within their institutions. Permission of the Publisher is required for resale \n\nor distribution \n\noutside the institution and for all other derivative works, including compilations and \n\ntranslations \n\n(please consult http://www.elsevier.com/permissions). If excerpts from other \n\ncopyrighted works are \n\nincluded, the author(s) must obtain written permission from the copyright owners \n\nand credit the \n\nsource(s) in the article. Elsevier has preprinted forms for use by authors in these \n\ncases: please consult \n\nhttp://www.elsevier.com/permissions. \n\nRetained author rights \nAs an author you (or your employer or institution) retain certain rights; for details \n\nyou are referred \n\nto: http://www.elsevier.com/journal-authors/author-rights-and-responsibilities. \n\nRole of the funding source \nYou are requested to identify who provided financial support for the conduct of the \n\nresearch and/or \n\npreparation of the article and to briefly describe the role of the sponsor(s), if any, in \n\nstudy design; in \n\nthe collection, analysis and interpretation of data; in the writing of the report; and \n\nin the decision to \n\nsubmit the article for publication. If the funding source(s) had no such involvement \n\nthen this should \n\nbe stated. Please see http://www.elsevier.com/funding. \n\nFunding body agreements and policies \nElsevier has established agreements and developed policies to allow authors whose \n\narticles appear in \n\njournals published by Elsevier, to comply with potential manuscript archiving \n\nrequirements as specified \n\nas conditions of their grant awards. To learn more about existing agreements and \n\npolicies please visit \n\nhttp://www.elsevier.com/fundingbodies. \n\nLanguage (usage and editing services) \nPlease write your text in good English (American or British usage is accepted, but \n\nnot \n\na mixture of these). Authors who feel their English language manuscript may \n\nrequire \n\n\n\n47 \n\n \n\n \n\nediting to eliminate possible grammatical or spelling errors and to conform to \n\ncorrect \n\nscientific English may wish to use the English Language Editing service available \n\nfrom \n\nElsevier's WebShop http://webshop.elsevier.com/languageediting/ or visit our \n\ncustomer support site \n\nhttp://support.elsevier.com for more information. \n\nSubmission \nSubmission to this journal proceeds totally online and you will be guided stepwise \n\nthrough the creation \n\nand uploading of your files. The system automatically converts source files to a \n\nsingle PDF file of the \n\narticle, which is used in the peer-review process. Please note that even though \n\nmanuscript source \n\nfiles are converted to PDF files at submission for the review process, these source \n\nfiles are needed for \n\nfurther processing after acceptance. All correspondence, including notification of the \n\nEditor's decision \n\nand requests for revision, takes place by e-mail removing the need for a paper trail. \n\nSubmit your article \nPlease submit your article via http://ees.elsevier.com/am/. \n\nReferees \nPlease submit, with the manuscript, the names, affiliations, and e-mail addresses of \n\n4 potential \n\nreferees. Note that the editor retains the sole right to decide whether or not the \n\nsuggested reviewers \n\nare used. \n\nPREPARATION \nUse of wordprocessing software \nIt is important that the file be saved in the native format of the wordprocessor \n\nused. The text should \n\nbe in single-column format. Keep the layout of the text as simple as possible. Most \n\nformatting codes \n\nwill be removed and replaced on processing the article. In particular, do not use the \n\nwordprocessor's \n\noptions to justify text or to hyphenate words. However, do use bold face, italics, \n\nsubscripts, \n\nsuperscripts etc. When preparing tables, if you are using a table grid, use only one \n\ngrid for each \n\nindividual table and not a grid for each row. If no grid is used, use tabs, not spaces, \n\nto align columns. \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 6 \n\nThe electronic text should be prepared in a way very similar to that of conventional \n\nmanuscripts \n\n(see also the Guide to Publishing with Elsevier: \n\nhttp://www.elsevier.com/guidepublication). Note that \n\nsource files of figures, tables and text graphics will be required whether or not you \n\nembed your figures \n\nin the text. See also the section on Electronic artwork. \n\nTo avoid unnecessary errors you are strongly advised to use the 'spell-check' and \n\n'grammar-check' \n\nfunctions of your wordprocessor. \n\nArticle structure \nGeneral guidelines for online submission: \n\nElsevier can accept text files in most standard word-processing formats but \n\nMicrosoft Word 97 is \n\n\n\n48 \n\n \n\n \n\npreferred. Alternatively, the initial submission can be in either PostScript or PDF \n\nformat. Please note, \n\nhowever, that the text file of a revision must be uploaded in an editable format, \n\neither Microsoft Word \n\nor LaTex. Graphics should be high-resolution and the preferred formats are either \n\nTIFF or JPEG. For \n\nfurther information on the preparation of electronic artwork please refer to the \n\nfollowing website: \n\nhttp://www.elsevier.com/artworkinstructions. \n\nPlease follow the instructions below for guidance on the style of the journal. Most \n\nformatting \n\ncodes are removed or replaced when your article is prepared for publication so \n\nthere is no need \n\nfor you to use excessive layout styling. However, please do not use options such as \n\nautomatic \n\nword breaking, justified layout, double columns or automatic paragraph numbering \n\n(especially for \n\nnumbered references). Do use bold face, italic, subscripts, superscripts, etc., as \n\nappropriate. Ensure \n\nthat each new paragraph is clearly indicated. When preparing tables, if you are \n\nusing a table grid, \n\nplease use only one grid for each separate table and not a grid for each row. If no \n\ngrid is being used, \n\nuse tabs to align columns instead of spaces. \n\nAll online submissions must be accompanied by a covering letter detailing what you \n\nare submitting. \n\nPlease indicate the author to whom correspondence should be addressed (in the \n\ncase of multiple \n\nauthors) and include a contact address, telephone/fax numbers for the \n\ncorresponding author and email \naddresses for all authors. Please include details of any previous or concurrent \n\nsubmissions and \n\nalso any information that will support your submission (e.g. original or confirmatory \n\ndata, relevance, \n\ntopicality). Please indicate if this is a resubmission of a paper previously rejected by \n\nan Acta Materialia \n\neditor and, if so, provide the manuscript number of the rejected paper along with \n\nthe name of the \n\nprocessing editor. (Referees are chosen carefully and all editorial decisions are \n\nconsidered final. In the \n\nevent of rebuttal by the authors, complete statements should be emailed directly to \n\nthe processing \n\neditor. The editor will invite resubmission if he determines that the argument \n\nsupports it.) Please note \n\nthat when your manuscript is received at Elsevier it is considered to be in its final \n\nform. Therefore \n\nyou need to check your manuscript carefully before you submit it online. \nLength of papers \n\nThe pressure for publication space in Acta Materialia is extreme. This situation may \n\nrequire the \n\nprocessing editor to impose a limitation on the length of a paper. Papers are \n\nnormally be less than \n\n10 printed pages in length; as a rule of thumb, a paper of 20 double-spaced \n\ntypescript pages, plus \n\na typical number of figures (8 or so) reduces to 10 printed pages. Use double \n\nspacing and minimum \n\n\n\n49 \n\n \n\n \n\n1-inch (3 cm) margins, and 12 pt font size standard fonts. Papers which are longer \n\nthan 25 doublespaced \n\ntypescript pages may be returned by the processing editor to the authors with a \n\nrequest that \n\nthey be shortened before being considered further. On the other hand, extremely \n\nshort papers less \n\nthan 3300 words will not be processed. Short communications and comments to \n\npapers published in \n\nActa Materialia should be submitted to Scripta Materialia. \nPagination \n\nPlease ensure that your manuscript is paginated, as this will help both editors and \n\nreviewers to process \n\nit promptly. \nSubdivision - numbered sections \n\nDivide your article into clearly defined and numbered sections. Subsections should \n\nbe numbered \n\n1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section \n\nnumbering). Use this \n\nnumbering also for internal cross-referencing: do not just refer to 'the text'. Any \n\nsubsection may be \n\ngiven a brief heading. Each heading should appear on its own separate line. \nIntroduction \n\nProvide a critical assessment of the literature relevant to the problem at hand, \n\ndelineating unresolved \n\nissues. State clear objectives to explain how this study will take the field forward. \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 7 \nExperimental \n\nProvide sufficient detail to allow the work to be reproduced. Methods already \n\npublished should be \n\nindicated by a reference: only relevant modifications should be described. \nError bars: \n\nError bars are required on all experimental and calculated data points with an \n\nexplanation in the text \n\nas to how the errors were determined. \nSI Units \n\nSI units should be used throughout. \nTheory/calculation \n\nA Theory section should extend, not repeat, the background to the article already \n\ndealt with in the \n\nIntroduction and lay the foundation for further work. In contrast, a Calculation \n\nsection represents a \n\npractical development from a theoretical basis. \nResults \n\nResults should be clear and concise. \nDiscussion \n\nShould develop cogent explanation for the results and explore their significance. In \n\nthe case \n\nof computational studies, results should be compared with information available \n\nfrom published \n\nexperimental work, if possible. \nConclusions \n\nThe main conclusions of the study may be presented in a short Conclusions section, \n\nwhich should \n\nstand alone. \nAppendices \n\nIf there is more than one appendix, they should be identified as A, B, etc. Formulae \n\nand equations in \n\n\n\n50 \n\n \n\n \n\nappendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a \n\nsubsequent appendix, \n\nEq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc. \n\nEssential title page information \n\u2022 Title. Concise and informative. Titles are often used in information-retrieval \n\nsystems. Avoid \n\nabbreviations and formulae where possible. \n\n\u2022 Author names and affiliations. Where the family name may be ambiguous (e.g., a \n\ndouble name), \n\nplease indicate this clearly. Present the authors' affiliation addresses (where the \n\nactual work was \n\ndone) below the names. Indicate all affiliations with a lower-case superscript letter \n\nimmediately after \n\nthe author's name and in front of the appropriate address. Provide the full postal \n\naddress of each \n\naffiliation, including the country name and, if available, the e-mail address of each \n\nauthor. \n\n\u2022 Corresponding author. Clearly indicate who will handle correspondence at all \n\nstages of refereeing \nand publication, also post-publication. Ensure that phone numbers (with country and \narea \ncode) are provided in addition to the e-mail address and the complete postal address. \nContact details must be kept up to date by the corresponding author. \n\n\u2022 Present/permanent address. If an author has moved since the work described in \n\nthe article was \n\ndone, or was visiting at the time, a 'Present address' (or 'Permanent address') may \n\nbe indicated as \n\na footnote to that author's name. The address at which the author actually did the \n\nwork must be \n\nretained as the main, affiliation address. Superscript Arabic numerals are used for \n\nsuch footnotes. \n\n\u2022It is not necessary to submit the title page as a separate document. However, if \n\nthis option is chosen, \n\nplease also include title page information at the beginning of the text document. \n\nAbstract \nAn abstract is required for all papers. The abstract should indicate the content of \n\nthe paper, and \n\nshould describe the main conclusions. An effective abstract is brief and normally \n\nless than 200 words. \n\nAbstracts should not exceed 250 words. References should be avoided, but if \n\nessential, they must be \n\ncited in full, without reference to the reference list. \n\nGraphical abstract \nA Graphical abstract is optional and should summarize the contents of the article in \n\na concise, pictorial \n\nform designed to capture the attention of a wide readership online. Authors must \n\nprovide images \n\nthat clearly represent the work described in the article. Graphical abstracts should \n\nbe submitted as a \n\nseparate file in the online submission system. Image size: Please provide an image \n\nwith a minimum \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 8 \n\nof 531 \u00d7 1328 pixels (h \u00d7 w) or proportionally more. The image should be readable \n\nat a size of 5 \u00d7 \n\n13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, \n\nPDF or MS Office \n\nfiles. See http://www.elsevier.com/graphicalabstracts for examples. \n\n\n\n51 \n\n \n\n \n\nAuthors can make use of Elsevier's Illustration and Enhancement service to ensure \n\nthe best \n\npresentation of their images also in accordance with all technical requirements: \n\nIllustration Service. \n\nKeywords \nImmediately following the Abstract, provide a maximum of 5 keywords which \n\nappropriately represent \n\nthe contents of the paper. The keywords must be selected from the Keywords list in \n\nthe most recently \n\npublished issue of the Journal (also available: Keyword Index) ; however, authors \n\nmay provide one \n\nkeyword (out of the five) which is not listed in the Keywords list. \n\nAbbreviations \nDefine abbreviations and acronyms when they first appear in the article. Ensure \n\nconsistency of \n\nabbreviations throughout the article. \n\nAcknowledgements \nCollate acknowledgements in a separate section at the end of the article before the \n\nreferences and do \n\nnot, therefore, include them on the title page, as a footnote to the title or \n\notherwise. List here those \n\nindividuals who provided help during the research (e.g., providing language help, \n\nwriting assistance \n\nor proof reading the article, etc.). \n\nMath formulae \nPresent simple formulae in the line of normal text where possible and use the \n\nsolidus (/) instead of \n\na horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to \n\nbe presented in \n\nitalics. Powers of e are often more conveniently denoted by exp. Number \n\nconsecutively any equations \n\nthat have to be displayed separately from the text (if referred to explicitly in the \n\ntext). \n\nFootnotes \nFootnotes should be used sparingly. Number them consecutively throughout the \n\narticle, using \n\nsuperscript Arabic numbers. Many wordprocessors build footnotes into the text, and \n\nthis feature may \n\nbe used. Should this not be the case, indicate the position of footnotes in the text \n\nand present the \n\nfootnotes themselves separately at the end of the article. Do not include footnotes \n\nin the Reference \n\nlist. \nTable footnotes \n\nIndicate each footnote in a table with a superscript lowercase letter. \n\nArtwork \nElectronic artwork \nGeneral points \n\n\u2022 Make sure you use uniform lettering and sizing of your original artwork. \n\n\u2022 Embed the used fonts if the application provides that option. \n\n\u2022 Aim to use the following fonts in your illustrations: Arial, Courier, Times New \n\nRoman, Symbol, or \n\nuse fonts that look similar. \n\n\u2022 Number the illustrations according to their sequence in the text. \n\n\u2022 Use a logical naming convention for your artwork files. \n\n\u2022 Provide captions to illustrations separately. \n\n\u2022 Size the illustrations close to the desired dimensions of the printed version. \n\n\n\n52 \n\n \n\n \n\n\u2022 Submit each illustration as a separate file. \n\nA detailed guide on electronic artwork is available on our website: \n\nhttp://www.elsevier.com/artworkinstructions \nYou are urged to visit this site; some excerpts from the detailed information are given \nhere. \nFormats \n\nIf your electronic artwork is created in a Microsoft Office application (Word, \n\nPowerPoint, Excel) then \n\nplease supply 'as is' in the native document format. \n\nRegardless of the application used other than Microsoft Office, when your electronic \n\nartwork is \n\nfinalized, please 'Save as' or convert the images to one of the following formats \n\n(note the resolution \n\nrequirements for line drawings, halftones, and line/halftone combinations given \n\nbelow): \n\nEPS (or PDF): Vector drawings, embed all used fonts. \n\nTIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of \n\n300 dpi. \n\nTIFF (or JPEG): Bitmapped (pure black &amp; white pixels) line drawings, keep to a \n\nminimum of 1000 dpi. \n\nTIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to \n\na minimum of \n\n500 dpi. \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 9 \nPlease do not: \n\n\u2022 Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these \n\ntypically have a \n\nlow number of pixels and limited set of colors; \n\n\u2022 Supply files that are too low in resolution; \n\n\u2022 Submit graphics that are disproportionately large for the content. \nColor artwork \n\nPlease make sure that artwork files are in an acceptable format (TIFF (or JPEG), \n\nEPS (or PDF), or \n\nMS Office files) and with the correct resolution. If, together with your accepted \n\narticle, you submit \n\nusable color figures then Elsevier will ensure, at no additional charge, that these \n\nfigures will appear in \n\ncolor on the Web (e.g., ScienceDirect and other sites) regardless of whether or not \n\nthese illustrations \nare reproduced in color in the printed version. For color reproduction in print, you will \nreceive \ninformation regarding the costs from Elsevier after receipt of your accepted article. \n\nPlease \n\nindicate your preference for color: in print or on the Web only. For further \n\ninformation on the \n\npreparation of electronic artwork, please see \n\nhttp://www.elsevier.com/artworkinstructions. \n\nPlease note: Because of technical complications which can arise by converting color \n\nfigures to 'gray \n\nscale' (for the printed version should you not opt for color in print) please submit in \n\naddition usable \n\nblack and white versions of all the color illustrations. \nFigure captions \n\nEnsure that each illustration has a caption. Supply captions separately, not \n\nattached to the figure. \n\n(A separate list of figure captions must be included in the main body of your paper, \n\nfollowing the \n\n\n\n53 \n\n \n\n \n\nreferences.) A caption should comprise a brief title (not on the figure itself) and a \n\ndescription of \n\nthe illustration. Keep text in the illustrations themselves to a minimum but explain \n\nall symbols and \n\nabbreviations used. \n\nTables \nNumber tables consecutively in accordance with their appearance in the text. Place \n\nfootnotes to tables \n\nbelow the table body and indicate them with superscript lowercase letters. Avoid \n\nvertical rules. Be \n\nsparing in the use of tables and ensure that the data presented in tables do not \n\nduplicate results \n\ndescribed elsewhere in the article. \n\nReferences \nAll references to other papers, books, etc., must be given at the end of the paper. \n\nThey should be \n\nnumbered in sequence starting at the beginning of the paper. The numbers (in \n\nbrackets) should \n\nappear in the text at the appropriate places. \nCitation in text \n\nPlease ensure that every reference cited in the text is also present in the reference \n\nlist (and vice \n\nversa). Any references cited in the abstract must be given in full. Unpublished \n\nresults and personal \n\ncommunications are not recommended in the reference list, but may be mentioned \n\nin the text. If these \n\nreferences are included in the reference list they should follow the standard \n\nreference style of the \n\njournal and should include a substitution of the publication date with either \n\n'Unpublished results' or \n\n'Personal communication'. Citation of a reference as 'in press' implies that the item \n\nhas been accepted \n\nfor publication. \nWeb references \n\nAs a minimum, the full URL should be given and the date when the reference was \n\nlast accessed. Any \n\nfurther information, if known (DOI, author names, dates, reference to a source \n\npublication, etc.), \n\nshould also be given. Web references can be listed separately (e.g., after the \n\nreference list) under a \n\ndifferent heading if desired, or can be included in the reference list. \nReferences in a special issue \n\nPlease ensure that the words 'this issue' are added to any references in the list (and \n\nany citations in \n\nthe text) to other articles in the same Special Issue. \nReference management software \n\nThis journal has standard templates available in key reference management \n\npackages EndNote (http://www.endnote.com/support/enstyles.asp) and Reference \n\nManager \n\n(http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing \n\npackages, authors only \n\nneed to select the appropriate journal template when preparing their article and the \n\nlist of references \n\nand citations to these will be formatted according to the journal style which is \n\ndescribed below. \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 10 \nReference style \n\n\n\n54 \n\n \n\n \n\nText: Indicate references by number(s) in square brackets in line with the text. The \n\nactual authors \n\ncan be referred to, but the reference number(s) must always be given. \n\nExample: \"..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different \n\nresult ....\" \nList: Number the references (numbers in square brackets) in the list in the order in \n\nwhich they appear \n\nin the text. \nExamples: \n\nReference to a journal publication: \n\n[1] van der Geer J, Hanraads JAJ, Lupton, RA. J Sci Commun 2000;163:51. \n\nReference to a book: \n\n[2] Strunk Jr. W, White EB. The Elements of Style, third ed. New York: Macmillan; \n\n1979. \n\nReference to a chapter in an edited book: \n\n[3] Mettam GR, Adams LB. How to prepare an electronic version of your article, in: \n\nJones BS, Smith \n\nRZ (Eds.). Introduction to the Electronic Age. New York: E Publishing Inc.; 1999. \nJournal abbreviations source \n\nJournal names should be abbreviated according to the \n\nList of title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php. \n\nVideo data \nElsevier accepts video material and animation sequences to support and enhance \n\nyour scientific \n\nresearch. Authors who have video or animation files that they wish to submit with \n\ntheir article are \n\nstrongly encouraged to include links to these within the body of the article. This can \n\nbe done in the \n\nsame way as a figure or table by referring to the video or animation content and \n\nnoting in the body \n\ntext where it should be placed. All submitted files should be properly labeled so that \n\nthey directly \n\nrelate to the video file's content. In order to ensure that your video or animation \n\nmaterial is directly \n\nusable, please provide the files in one of our recommended file formats with a \n\npreferred maximum \n\nsize of 50 MB. Video and animation files supplied will be published online in the \n\nelectronic version \n\nof your article in Elsevier Web products, including ScienceDirect: \n\nhttp://www.sciencedirect.com. \n\nPlease supply 'stills' with your files: you can choose any frame from the video or \n\nanimation or \n\nmake a separate image. These will be used instead of standard icons and will \n\npersonalize the \n\nlink to your video data. For more detailed instructions please visit our video \n\ninstruction pages at \n\nhttp://www.elsevier.com/artworkinstructions. Note: since video and animation \n\ncannot be embedded \n\nin the print version of the journal, please provide text for both the electronic and \n\nthe print version \n\nfor the portions of the article that refer to this content. \n\nAudioSlides \nThe journal encourages authors to create an AudioSlides presentation with their \n\npublished article. \n\nAudioSlides are brief, webinar-style presentations that are shown next to the online \n\narticle on \n\n\n\n55 \n\n \n\n \n\nScienceDirect. This gives authors the opportunity to summarize their research in \n\ntheir own words and \n\nto help readers understand what the paper is about. More information and \n\nexamples are available at \n\nhttp://www.elsevier.com/audioslides. Authors of this journal will automatically \n\nreceive an invitation \n\ne-mail to create an AudioSlides presentation after acceptance of their paper. \n\nSupplementary data \nElsevier accepts electronic supplementary material to support and enhance your \n\nscientific research. \n\nSupplementary files offer the author additional possibilities to publish supporting \n\napplications, highresolution \n\nimages, background datasets, sound clips and more. Supplementary files supplied \n\nwill be \n\npublished online alongside the electronic version of your article in Elsevier Web \n\nproducts, including \n\nScienceDirect: http://www.sciencedirect.com. In order to ensure that your \n\nsubmitted material is \n\ndirectly usable, please provide the data in one of our recommended file formats. \n\nAuthors should \n\nsubmit the material in electronic format together with the article and supply a \n\nconcise and descriptive \n\ncaption for each file. For more detailed instructions please visit our artwork \n\ninstruction pages at \n\nhttp://www.elsevier.com/artworkinstructions. \n\nSubmission checklist \nIt is hoped that this list will be useful during the final checking of an article prior to \n\nsending it to the \n\njournal's Editor for review. Please consult this Guide for Authors for further details \n\nof any item. \nEnsure that the following items are present: \n\nOne Author designated as corresponding Author: \n\n\u2022 E-mail address \n\n\u2022 Full postal address \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 11 \n\n\u2022 Telephone and fax numbers \n\n\u2022Email addresses provided for all authors \n\nAll necessary files have been uploaded \n\n\u2022 Keywords \n\n\u2022 All figure captions \n\n\u2022 All tables (including title, description, footnotes) \n\nFurther considerations \n\n\u2022 Manuscript has been \"spellchecked\" and \"grammar-checked\" \n\n\u2022 References are in the correct format for this journal \n\n\u2022 All references mentioned in the Reference list are cited in the text, and vice versa \n\n\u2022 Permission has been obtained for use of copyrighted material from other sources \n\n(including the Web) \n\n\u2022 Color figures are clearly marked as being intended for color reproduction on the \n\nWeb (free of charge) \n\nand in print or to be reproduced in color on the Web (free of charge) and in black-\n\nand-white in print \n\n\u2022 If only color on the Web is required, black and white versions of the figures are \n\nalso supplied for \n\nprinting purposes \n\nFor any further information please visit our customer support site at \n\nhttp://epsupport.elsevier.com. \n\nAFTER ACCEPTANCE \n\n\n\n56 \n\n \n\n \n\nUse of the Digital Object Identifier \nThe Digital Object Identifier (DOI) may be used to cite and link to electronic \n\ndocuments. The DOI \n\nconsists of a unique alpha-numeric character string which is assigned to a \n\ndocument by the publisher \n\nupon the initial electronic publication. The assigned DOI never changes. Therefore, \n\nit is an ideal \n\nmedium for citing a document, particularly 'Articles in press' because they have not \n\nyet received their \n\nfull bibliographic information. Example of a correctly given DOI (in URL format; \n\nhere an article in the \njournal Physics Letters B): \n\nhttp://dx.doi.org/10.1016/j.physletb.2010.09.059 \n\nWhen you use a DOI to create links to documents on the web, the DOIs are \n\nguaranteed never to \n\nchange. \n\nProofs \nOne set of page proofs (as PDF files) will be sent by e-mail to the corresponding \n\nauthor (if we do \n\nnot have an e-mail address then paper proofs will be sent by post) or, a link will be \n\nprovided in \n\nthe e-mail so that authors can download the files themselves. Elsevier now provides \n\nauthors with \n\nPDF proofs which can be annotated; for this you will need to download Adobe \n\nReader version 7 (or \n\nhigher) available free from http://get.adobe.com/reader. Instructions on how to \n\nannotate PDF files \n\nwill accompany the proofs (also given online). The exact system requirements are \n\ngiven at the Adobe \n\nsite: http://www.adobe.com/products/reader/tech-specs.html. \n\nIf you do not wish to use the PDF annotations function, you may list the corrections \n\n(including \n\nreplies to the Query Form) and return them to Elsevier in an e-mail. Please list your \n\ncorrections \n\nquoting line number. If, for any reason, this is not possible, then mark the \n\ncorrections and any other \n\ncomments (including replies to the Query Form) on a printout of your proof and \n\nreturn by fax, or scan \n\nthe pages and e-mail, or by post. Please use this proof only for checking the \n\ntypesetting, editing, \n\ncompleteness and correctness of the text, tables and figures. Significant changes to \n\nthe article as \n\naccepted for publication will only be considered at this stage with permission from \n\nthe Editor. We will \n\ndo everything possible to get your article published quickly and accurately \u2013 please \n\nlet us have all your \n\ncorrections within 48 hours. It is important to ensure that all corrections are sent \n\nback to us in one \n\ncommunication: please check carefully before replying, as inclusion of any \n\nsubsequent corrections \n\ncannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier \n\nmay proceed with \n\nthe publication of your article if no response is received. \n\nOffprints \nThe corresponding author, at no cost, will be provided with a PDF file of the article \n\nvia email \n\n\n\n57 \n\n \n\n \n\n(the PDF file is a watermarked version of the published article and includes a cover \n\nsheet \n\nwith the journal cover image and a disclaimer outlining the terms and conditions of \n\nuse). For \n\nan extra charge, paper offprints can be ordered via the offprint order form which is \n\nsent once \n\nthe article is accepted for publication. Both corresponding and co-authors may \n\norder offprints \n\nat any time via Elsevier's WebShop \n\n(http://webshop.elsevier.com/myarticleservices/offprints). \n\nAuthors requiring printed copies of multiple articles may use Elsevier WebShop's \n\n'Create Your Own Book' service to collate multiple articles within a single cover \n\n(http://webshop.elsevier.com/myarticleservices/offprints/myarticlesservices/bookle\n\nts). \n\nAUTHOR INFORMATION PACK 22 Aug 2013 www.elsevier.com/locate/actamat 12 \n\nAUTHOR INQUIRIES \nFor inquiries relating to the submission of articles (including electronic submission) \n\nplease visit \n\nthis journal's homepage. For detailed instructions on the preparation of electronic \n\nartwork, \n\nplease visit http://www.elsevier.com/artworkinstructions. Contact details for \n\nquestions arising after \n\nacceptance of an article, especially those relating to proofs, will be provided by the \n\npublisher. \n\nYou can track accepted articles at http://www.elsevier.com/trackarticle. You can \n\nalso check \n\nour Author FAQs at http://www.elsevier.com/authorFAQ and/or contact Customer \n\nSupport via \n\nhttp://support.elsevier.com. \n\u00a9 Copyright 2012 Elsevier | http://www.elsevier.com"}]}}}